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 Salmonella enterica continues to be a significant public health concern, 
causing an estimated 93.8 million cases of non-typhoidal salmonellosis and 21 
million cases of typhoid fever worldwide each year.  There are thousands of 
Salmonella enterica serovars, some with a very specific host set, and others that 
cause disease in rodents, birds, livestock, domestic fowl, and humans alike.  In 
recent years, there has been much progress in the delineation of Salmonella 
infection, with the goal of understanding Salmonella pathogenesis at the 
molecular level.  Salmonella produces many different effector proteins capable of 
interacting with and altering numerous biological pathways in the host – enabling 
host invasion and intracellular survival as well as dissemination and 
transmission. 
We used X-ray crystallography to characterize Gifsy-2 Gene E (GtgE), an 
effector protease from broad-host serovars of Salmonella, that affords these 
serovars, at least in part, with the ability to maintain a diverse host repertoire.  
GtgE modulates vesicular trafficking of the Salmonella-containing vacuole by 
cleaving Rab GTPases, Rab29, Rab32, and Rab38, thereby preventing the 
delivery of antimicrobial products to the vacuole.  In order to gain an 
understanding of GtgE’s proteolytic mechanism, we determined the structure of 
GtgE to 1.65Å using single-wavelength anomalous diffraction, and through 
structure-based mutagenesis and in vitro activity assays, we established the 
catalytic triad of GtgE, Cys45-His151-Asp169.  We also examined a panel of 
cysteine protease inhibitors and found that N-ethylmaleimide, chymostatin, and 
antipain were capable of inhibiting GtgE activity in vitro.  Furthermore, through 
work with the catalytically inactive mutant of GtgE (GtgE-C45A), we were able to 
identify the conditions necessary to form a stable complex between GtgE and 
Rab38, which may prove useful for further structural work and reveal the nature 
of GtgE’s interaction with its Rab GTPase substrates.  
 Additionally, we investigated SipC, a Salmonella translocase protein with 
two effector domains – an N-terminal actin bundling domain and a C-terminal 
actin nucleation domain.  We sought to define minimal constructs of these 
effector domains for crystallization studies, and obtained needle-like spherulites 
with the C-terminal domain.  We also showed that mouse Exo70 is able to pull-
down the C-terminal domain of SipC from cell lysate.  Finally, we examined 
Salmonella effector AvrA, which has been attributed with having deubiquitinase 
and acetyltransferase activity, although its role in Salmonella pathogenesis 
remains poorly understood.  We determined a minimal construct of AvrA that 
contains the proposed catalytic triad, and through a yeast two-hybrid experiment, 
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CHAPTER 1.  INTRODUCTION 
 
 
1.1  Salmonella enterica 
 
 
Salmonella enterica (S. enterica) is a rod-shaped, flagellated, Gram-negative 
bacterium comprised of six subspecies [1].  Of these subspecies, only one, 
Salmonella enterica subspecies enterica, is capable of causing disease in 
vertebrate animals [1].  S. enterica subspecies enterica is further divided into 
thousands of serovars distinguished by the antigenic polymorphisms of their 
flagellar, carbohydrate, and lipopolysaccharide structures [2, 3].  These serovars 
vary in their host specificity.  Salmonella enterica serovar typhimurium (S. 
typhimurium) is a broad-host serovar that is capable of infecting a wide range of 
hosts.  On the other end of the spectrum, Salmonella enterica serovar typhi (S. 
typhi) is a human-adapted serovar, only causing disease in higher primates [4].  
Host-specificity is believed to have evolved through the acquisition of new 
genetic material via horizontal gene transfer and loss of functional genes through 
genome degradation [5].  Genetic degradation, which involves the loss of genetic 
information by gene deletion or pseudogene formation, is evident in strains of S. 
typhi; 210 pseudogenes have been identified in S. typhi, while only 39 








1.2  Pathogenesis 
 
 
S. enterica infection can manifest itself as gastroenteritis, Typhoid 
(enteric) fever, bacteremia, or chronic asymptomatic carriage [2].  In humans, the 
severity of disease caused by S. enterica subspecies enterica varies based on 
host health as well as the identity of the infecting serovar [3].  Nontyphoidal 
Salmonella poses a considerable global health threat, and in 2010, there were 
93.8 million cases estimated worldwide, of which approximately 155,000 resulted 
in death [10].  Of the more than 21 million cases of typhoid fever reported 
worldwide each year, upwards of 200,000 result in death, mostly in 
underdeveloped countries [11].  Those infected with S. typhi are prone to 
symptom relapse, and multidrug-resistant strains of S. typhi capable of infecting 
otherwise healthy individuals are widespread, making S. typhi a significant 
global-health concern [11-13]. 
 
In humans, S. enterica is predominantly acquired through fecal-oral 
transmission, typically via the ingestion of contaminated food or water.  S. 
enterica is able to survive the low pH of the stomach, going on to colonize the 
endothelial cells of the gastrointestinal tract [14].  Other S. enterica targets 
include: macrophages, neutrophils, monocytes, dendritic cells, granulocytes, M 
cells, B cells, and T cells [15].  Infection of the gut epithelial cells is known as 
gastroenteritis, and accounts for roughly 26% of food poisoning cases in the 
United States [14, 16].  Gastroenteritis is characterized by the acute onset of 
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fever, chills, nausea, vomiting, abdominal cramping, and diarrhea [17].  Although 
this infection is usually self-limiting, it can cause death in infants, the elderly, and 
immunocompromised individuals [17].       
 
1.2.1  Salmonella Pathogenicity Island-1: Intestinal Invasion 
 
Before host cell invasion can occur, the bacterial cells adhere to the 
intestinal epithelial cell surface using fimbriae, which are short, proteinaceous 
structures extending from the bacterial surface that mediate attachment and can 
confer attachment specificity [3, 14].  This adherence is reversible and in order to 
irreversibly dock to and invade the host, Salmonella relies on the actions of 
various proteins encoded by Salmonella pathogenicity islands, plasmids, 
functional prophages, and phage remnants [18, 19].  Salmonella pathogenicity 
islands are large, virulence factor-containing segments of DNA that are inserted 
into chromosomal DNA, usually flanked by direct repeats and associated with 
tRNA loci and insertion sequence (IS) elements [3, 20].  These pathogenicity 
islands often contain mobility genes, such as integrases, transposases, IS 
elements, and origins of plasmid replication, and have a lower G-C content, 
roughly 37-47%, than is typical for bacterial chromosomal DNA, which has a 52% 
G-C content [20].  Salmonella pathogenicity island I (SPI-1) is activated upon 
docking and contains the genetic information necessary to produce and 





















Figure 1.  The type III secretion system.  The T3SS apparatus is comprised of 
an inner (orange) and outer (red) ring that allow for passage through the inner 
and outer bacterial membranes, and are linked by a neck domain (blue).  The 
needle (green) is anchored at the base of the neck via the inner rod, and extends 
from the surface of the bacterial cell [21].  The translocon pore (purple) is formed 
by an oligomerization of two bacterial effector/translocase proteins.  This system 
creates a pathway through which bacterial effector proteins can travel from the 
bacterial cytoplasm into the host.  EM images adapted from Schraidt, et al. and 













T3SS1 is a needle-like structure, often referred to as the injectisome, that 
serves as a molecular syringe with the ability to deliver bacterial effector proteins 
directly into the host cell (Fig. 1).  T3SS1 is one of at least six different secretion 
systems found in Gram-negative bacteria, and is believed to be evolutionarily 
related to the bacterial flagellum [24].  The needle apparatus is composed of four 
main parts: inner rings, a membrane-spanning neck, outer rings, and an external 
needle complex (Fig. 1).  In addition to these components, which are physically 
associated with the bacterial cell, T3SS1 also includes a pore complex, the 
translocon, that assembles within the host cell membrane [25].  Taken together, 
the T3SS1 components create a pathway through which effector proteins, 
proteins that possess the ability to modulate cellular mechanisms in the host, can 
travel from the bacterial cytoplasm into the host cytoplasm.  
 
An alternative hypothesis for effector translocation, in which the T3SS 
effector mechanism functions similarly to the AB toxin delivery system, was 
recently proposed by Edgren, et al. [26].  The authors suggest a two-step model 
for translocation of effector proteins that entails: first, the secretion of 
translocases and effectors; and second, the translocation of effectors into the 
host cell upon host cell contact.  Translocation is predicted to occur in an AB 
toxin-like fashion, where the translocase acts as the pore-forming B subunit and 
the effector functions as the catalytic A subunit.  In this model, the needle 
complex serves as a sensory structure used to identify the host cell, and as a 
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pathway for the extracellular secretion of effectors [26].  This translocation 
mechanism is based on data gathered on Yersinia, another bacterial species 
utilizing a T3SS, showing that both Yersinia Yop translocases and effector 
proteins are present on the bacterial surface prior to host cell contact [27], and 
that a complex of translocases YopB and YopD with effector YopE occurs 
extracellularly, prior to host invasion [28].  Further support has come from a study 
by Rosqvist, et al. that identifies two Yersinina effectors, YopE and YopD, as 
having AB toxin activity [29].  However, it remains unclear whether the proposed 
AB toxin-like translocation mechanism applies only to Yersinia or if it can be 
extended to all T3SS-utilizing bacteria as well.  To date, translocase homologs in 
Shigella and Salmonella have not been shown to have AB toxin activity, nor have 
extracellular intermediate translocase-effector complexes been identified in 
Shigella or Salmonella, although the translocase proteins do appear to associate 
prior to translocon formation [30, 31].  Since direct evidence for the translocon is 
lacking and the methods of translocase insertion and translocon formation remain 
unknown, additional studies will be required in order to discern the true mode of 
effector translocation. 
 
Once translocated into the host, effector proteins interact with and alter 
host pathways in a variety of ways.  The initial wave of delivered effectors 
performs various functions aimed at encouraging host uptake of the bacterial cell, 
including stimulating GTPase activation and actin polymerization in order to 
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induce the phagocytic engulfment of the Salmonella cell by the host [32].  As the 
bacterial cell enters the host it becomes enveloped in a membrane-bound 
vesicle, termed the Salmonella-containing vacuole (SCV), which undergoes a 
maturation process and serves as the site of replication for the bacterium [33] 























Figure 2.  Salmonella enters the host cell.  In order to invade its host, 
Salmonella injects effector proteins into the host cell that stimulate the 
bacterium’s uptake and enable it to survive and replicate inside the Salmonella-











1.2.2  Salmonella Pathogenicity Island-2: Survival and Replication  
 
 
Upon internalization, Salmonella begins expressing SPI-2-encoded 
effector proteins in response to various environmental cues, such as low 
osmolarity, acidification of the SCV, and decreased levels of certain nutrients 
[34].  SPI-2 also encodes a second T3SS, T3SS2, which is structurally similar to 
that of T3SS1.  T3SS2 functions to transport bacterial effectors across the SCV 
membrane and into the host cytoplasm where they can then interact with their 
targets [14].  Salmonella utilizes a variety of different effector proteins to 
attenuate the host’s defense mechanisms and increase its chances for survival 
and replication inside the SCV [3]. 
 
T3SS2 also plays a role in the biogenesis of the SCV, which is a modified 
phagosome with characteristics of a late endosome [35].  The eukaryotic 
endocytic pathway is a degradation pathway that involves endosome maturation 
and subsequent development into a functional hydrolytic phagolysosome for 
cargo degradation [36].  In its early stage of biogenesis, the SCV shows the 
transient presence of early endocytic markers, mainly EEA1, Rab GTPase 5, and 
transferrin receptor [37].  These markers are replaced by the late endocytic 
indicators: lysosomal-associated membrane proteins (LAMP) 1 and 2, vacuolar 
ATPase (vATPase), and cholesterol [36, 38, 39].  LAMP1 and LAMP2 are 
integral membrane proteins involved in membrane fusion and the biogenesis of 
lysosomes, and are often present in late endosomes.  V-ATPase causes the 
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acidification of the SCV lumen, and during this stage, the SCV moves into a 
juxtanuclear position proximal to the microtubule organizing center [40-42].  At 
this point in development, Salmonella begins replicating inside the SCV, and 
extensive membrane tubules, or Salmonella-induced filaments, begin to form, 
originating from the SCV and projecting throughout the host cell [43, 44].  The 
SCV is able to circumvent the degradation step of the endocytic pathway by 
preventing the assembly of a functional hydrolytic phagolysosome [36].    
 
1.2.3  Dissemination and Transmission 
 
In order to continue propagation, S. enterica must move from one host to 
the next.  There are several mechanisms by which Salmonella can cause host 
cell death and enable its escape from the host: epithelial cell apoptosis, rapid 
T3SS1-dependent pyroptosis, and delayed T3SS2-dependent macrophage 
pyroptosis [45].  Apoptosis of the host is a form of programmed cell death that 
involves the dismantling of the cell by executioner caspases and phagocytosis of 
the resulting apoptotic bodies by phagocytic cells without eliciting an 
inflammatory response [45].  During the replication phase, Salmonella is able to 
delay apoptosis for 12-18 hours in its epithelial host, creating a more stable 
intracellular environment for ample proliferation, and when ready to leave the 
host, the bacterium triggers apoptosis in epithelial cells through the actions of 
T3SS1 and T3SS2 effectors [18, 46, 47].    
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In macrophages, S. enterica can cause either a rapid T3SS1-dependent or 
a delayed T3SS2-dependent programmed cell death known as pyroptosis [18].  
Unlike apoptosis, pyroptosis is a proinflammatory pathway dependent on 
caspase-1 activation, which mounts an immune response that terminates in cell 
lysis [45, 48].  During rapid T3SS1-dependent pyroptosis, several T3SS1 
effectors function together with caspase-1 to cause cell lysis within 2-3 hours 
post-infection [49].  In contrast, delayed T3SS2-dependent pyroptosis relies on 
specific T3SS2 effector proteins and caspase-1 activity to cause apoptosis-like 
macrophage death 18-24 hours post-infection [50].  Salmonella employs rapid or 
delayed pyroptosis depending on the given physiological conditions, tissue 
location, and stage of infection [49].  Rapid pyroptosis occurs during the intestinal 
phase of infection, and may aid in systemic spread of infection through the 
recruitment of phagocytes and increased inflammation [49].  Once systemic, 
delayed pyroptosis is utilized for intracellular spread at the site of infection by 
stimulating the formation of Salmonella-containing apoptotic bodies that are then 
engulfed by neighboring macrophages [49, 50].  Through these cell death 
mechanisms, S. enterica is able to spread between cells within an organism as 










1.2.4  S. typhi Pathogenesis 
 
 
In humans, S. typhi infection poses a much more serious health concern 
than does S. typhimurium, as it causes a systemic infection even in healthy 
individuals.  This systemic infection, Typhoid fever, requires a 1-3 week 
incubation period, in which time the bacteria travels through the bloodstream, 
predominately targeting the liver, spleen, gall bladder, and bone marrow [19, 51].  
The underlying mechanistic differences responsible for the dramatic contrast in 
S. typhimurium and S. typhi disease outcome are largely unknown.  Both 
pathogens enter the human host orally and initially reside and replicate inside the 
SCV.     
 
Unlike S. typhimurium, which stimulates a substantial neutrophil influx into 
the intestines and is accompanied by diarrhea, S. typhi infection does not lead to 
significant intestinal inflammation and only a third of cases develop diarrhea [4].  
S. typhi expresses the Vi antigen, a capsular polysaccharide, on its surface 
during intestinal infection.  The Vi antigen down-regulates the Toll-like receptor-
mediated host response that induces neutrophil infiltration; thus, through Vi 
antigen expression, S. typhi is able to colonize deeper body tissues [52-54].  
 
Another distinguishing feature of S. typhi is that it produces and secretes a 
typhoid toxin, which is similar to the cytolethal distending toxin (CDT) produced 
by many other Gram-negative bacterial pathogens [55].  Typhoid toxin, like CDT, 
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is an AB toxin that possesses DNase and ADP-ribosyl transferase activities and 
is capable of translocating to the host nucleus, making double-strand breaks in 
DNA and ultimately leading to cell cycle arrest and apoptosis in the host [55-57].  
This toxin is expressed once S. typhi reaches an intracellular location, and it is 
then transported outside the host through a series of vesicular transport 
intermediates where it is able to induce apoptosis in infected and uninfected 
neighboring cells [56, 58, 59].  By causing apoptosis in the host tissue, CDT 
toxins enable bacterial colonization, persistent infection, and chronic disease 
[57].  S. typhi is able to persist in infected tissues and evade immune defenses 
by residing inside host cells that lack CDT receptors, and therefore, are not 
susceptible to typhoid toxin action [58].  This persistence allows S. typhi to infect 
humans for extended periods of time, and even for life, if the infection goes 
untreated.   
 
1.3  Gifsy-2 Gene E Effector Protein 
 
Another distinguishing factor between S. typhimurium and S. typhi is the 
presence of effector protease Gifsy-2 Gene E (GtgE) [56, 60].  GtgE, which is 
required for full virulence of S. typhimurium, is one of two virulent genes located 
on the Gifsy-2 bacteriophage and is secreted in a SPI-1 T3SS-dependent manner 
[56, 61].  GtgE proteolytically cleaves and inactivates its Rab GTPase substrates 
(Rab29, Rab32, Rab38), enabling S. typhimurium to evade the host’s 
antimicrobial defenses as it carries out its lifecycle within the SCV.  Expression of 
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GtgE in S. typhi allows the pathogen to overcome some of its host restriction 
barrier to infect mouse macrophages, which is likely due to the pathogen’s ability 
to better elude host microbial defenses [60].  In wild-type S. typhi infection, the 
recruitment of Rab29 to the SCV aids in the formation of toxin transport 
intermediates, ultimately facilitating a systemic S. typhi infection [56].  
 
As GtgE’s biological role has only recently been discerned, little is 
understood as to how the protease performs its catalytic function.  GtgE is a 
26kD protein, 228 residues in length, with predicted C-terminal homology to 
known papain-like cysteine proteases as determined by HHpred [62].  This C-
terminal homology does not span the entire active site of GtgE, making functional 
predictions about the enzyme fairly ambiguous.  Through our structural and 
biochemical studies detailed in this work, we have determined that GtgE 
functions as a cysteine protease and have identified the catalytic residues 




























Figure 3.  The activity cycle of Rab GTPases.  Rab GTPases cycle 
between GDP- and GTP-bound states with the aid of GTPase-activating 
proteins (GAPs) and guanine nucleotide exchange factors (GEFs).  The GTP-
bound state primes the Rab for interaction with its specific, membrane-
localized cellular target.  Figure adapted from Stenmark, et al. and Ebine, et 
al. [63, 64]. 
 
 
In humans, the Rab GTPase family, which falls within the Ras superfamily 
of small G proteins, contains more than 60 members that are localized to distinct 
intracellular membranes based on the sequence variation and prenylation of their 
C-terminal domain [65].  Rab GTPases cycle between inactive and active states, 
















regulation of membrane trafficking, cell growth, and differentiation (Fig. 3) [65, 
66].  Although Rabs have intrinsic GTPase activity, they require the aid of several 
different interacting partners for adequate function [63].  The Rab activity cycle 
begins upon prenylation and consequent delivery of the Rab to its target 
membrane by accessory factors known as Rab escort proteins (REPs) [67].  
Nucleotide exchange, GDP to GTP, and activation of Rab is facilitated by 
guanine nucleotide exchange factors (GEFs), which are unique to each Rab [63].  
GTPase-activating proteins (GAPs) accelerate the hydrolysis of GTP by Rab, 
stimulating the given downstream effect [68, 69].  Following hydrolysis, the Rab is 
bound to GDP and the GAP is replaced by a GDP dissociation inhibitor (GDI), 
which displaces Rab from the membrane and sequesters it in the cytoplasm until 
the next transport cycle begins [67]. 
 
Rab GTPases are typically small proteins, roughly 20-25kD, and share an 
overall fold containing a six-stranded β sheet surrounded by five α helices [70].  
The residues responsible for interacting with the guanine nucleotide and 
magnesium ion, an essential cofactor for nucleotide binding, reside in the loop 
regions connecting the β strands and α helices [64, 71].  The nucleotide-binding 
pocket on these Rab proteins is formed by two highly conserved regions termed 
Switch I and Switch II (Fig. 4A).  These regions confer functional specificity to the 
Rabs and serve as recognition sites for effector proteins because they make 
dramatic conformational changes based on the identity of the bound nucleotide 
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[72, 73].  GtgE cleaves its Rab substrate between a glycine and valine located 
within the switch I region (Fig. 4B) and in doing so, presumably destroys the 








Figure 4.  The Rab GTPase substrates.  (A) The alignment of full-length 
Rab29, Rab32, and Rab38.  Sequence homology is depicted on a color scale 
ranging from red (high homology) to blue (low homology).  Key structural 
motifs, Switch I and Switch II, are indicated.  Alignment generated in T-Coffee 
[74].  (B) The GtgE cleavage site of Rab38, TIGVDF, which corresponds to 
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GtgE’s substrates, Rab29, Rab32, and Rab38, are closely related Rab 
GTPases that form their own subclass within the Rab GTPase family [60, 66].  As 
illustrated in Figure 4A, Rab29, Rab32, and Rab38 share high homology 
throughout much of their primary sequence, but differ in their C-terminal tail, 
which is expected because these GTPases have different cellular targets.  Rab32 
and Rab38 have been implicated in the biogenesis of lysosome-related 
organelles (i.e. melanosomes, specialized granules in platelet and T cells, and 
the Salmonella-containing vacuole) and coordinate the delivery of cargo to these 
organelles [60, 75-77].  In combination with BLOC-1, -2, -3, Rab32 and Rab38 
allow for the delivery of antimicrobial proteins to the SCV, consequently leading 
to pathogen death [60, 76, 78].  Through cleavage of Rab32 and Rab38, GtgE is 
able to circumvent this particular host cell defense pathway.  Rab29 remains 
uncharacterized thus far [66].  Rab29 is known to associate with the Golgi 
complex as well as with lengthy, dynamic tubules extending from the Golgi body, 
and it is has been shown that Rab29 is required for the formation of typhoid toxin 














CHAPTER 2.  MATERIALS AND METHODS 
 
 
2.1  Protein Expression and Purification 
 
 
Salmonella typhimurium LT2 GtgE 1-228, GtgE79-214, and all other GtgE 
constructs were cloned into a modified pCDF-Duet-1 vector (Novagen) between 
the SalI and NotI restriction sites.  All GtgE1-228 point mutants were generated by 
site-directed mutagenesis.  GtgE43-214,Δ74-79 was generated by PCR amplifying 
GtgE43-73 and GtgE80-214 and stitching the two pieces together via PCR 
amplification.  Protein was expressed in E. coli BL21(DE3) cells with 0.75mM 
IPTG for 16 hours at 18°C.  Selenomethionine-substituted GtgE79-214 was 
expressed in E. coli 834 cells in selenomethionine-supplemented minimal media 
with 0.75mM IPTG at 18°C for 12 hours.  Harvested cells were pelleted, 
resuspended in 50mM Tris-HCl, pH 8.0, 300mM NaCl, and 5mM imidazole, and 
lysed via high-pressure homogenization.  Cleared lysate was run over Ni-NTA 
resin (Qiagen) and protein was eluted in 50mM Tris-HCl, pH 8.0, 300mM NaCl, 
and 500mM Imidazole.  Protein was dialyzed against 25mM Tris-HCl, pH 8.0, 
250mM NaCl, and 5mM DTT, and the N-terminal Histidine tag was cleaved off 
with 6xHis-rhinovirus 3C protease.  The material was passed over Ni-NTA to 
remove the histidine tag and 3C protease.  The final purification step was size 
exclusion chromatography using a Superdex 75, 120mL column (GE Healthcare).  
Native and selenomethionine-substituted GtgE79-214 was purified into 25mM 
HEPES, pH 8.0, 250mM NaCl, and 5mM DTT.  GtgE1-228 constructs were purified 
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into 25mM Tris-HCl, pH 8.0, 250mM NaCl, and 5mM DTT.  Purified protein was 
stable at -80°C for up to 3 months. 
 
Human Rab381-211 was cloned into a modified pCDF-Duet-1 vector 
(Novagen) between the SalI and NotI restriction sites.  Purification was carried 
out identically to the purification of GtgE; however, all Rab381-211 buffers 
contained 5mM MgCl2 and final purification was done on a Superdex 200, 120mL 
column (GE Healthcare) into 25mM Tris-HCl, pH 8.0, 250mM NaCl, 5mM MgCl2, 
5mM DTT.  Purified protein was stored at -80°C. 
 
To form the complex of GtgE and Rab29/Rab38, GtgE and its Rab 
substrate were co-expressed from a modified pCDF-Duet-1 vector (Novagen).  
Rab29 or Rab38 was cloned between the SalI and NotI restriction sites and was 
N-terminally histidine-tagged.  GtgE was cloned into the tag-free second cloning 
site between NdeI and XhoI restriction sites.  Protein was expressed in E. coli 
BL21(DE3) cells with 0.75mM IPTG for 16 hours at 18°C.  The complex was 
purified according to the purification conditions used for Rab381-211, and during 
the final Superdex 200, 120mL column (GE Healthcare) run, the material was 
exchanged into 25mM Tris-HCl, pH 8.0, 250mM NaCl, 5mM DTT, and 100μM 
MgCl2.  Combinations of different GtgE and Rab29/Rab38 point mutants were 
generated by site-directed mutagenesis and were expressed and purified 
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according to the protocol described for the wild-type complex.  The point mutants 
used in this work are detailed in Table 4.  Purified protein was stored at -80°C. 
 
 
2.1.1  Urea Denaturation and Dialysis-based Refolding 
 
 
Protein was expressed from E. coli BL21(DE3) cells and lysed as 
previously described.  Lysate was cleared via centrifugation, and the resulting 
pellet (insoluble fraction) was resuspended in 6M urea, 0.5M NaCl, and 20mM 
Tris-HCl pH 8.0.  Resuspended material was centrifuged at 16,000 rpm for 40 
minutes, and the supernatant was applied to NiNTA resin (Qiagen) that had been 
equilibrated in 6M urea, 0.5M NaCl, and 20mM Tris-HCl pH 8.0.  The column was 
washed with 6M urea, 0.5M NaCl, 30mM imidazole, and 20mM Tris-HCl pH 8.0.  
Protein was eluted with 6M urea, 0.5M NaCl, 500mM imidazole, and 20mM Tris-
HCl pH 8.0.  All work was done at room temperature. 
 
Refolding was performed through four rounds of dialysis at 4°C in 20mM 
Tris-HCl pH 8.0, 250mM NaCl, 5% glycerol, 2mM EDTA, and 5mM DTT.  The 
protein sample was diluted to approximately 0.1 mg/mL, and the protein to 
refolding buffer volume ratio did not exceed 1:20.  The first three rounds of 
dialysis were 2-4 hours in length.  For the final round, which was allowed to 
dialyze for 16 hours, glycerol and EDTA were removed from the buffer and the 
samples were treated with 6xHis-rhinovirus 3C protease to cleave the histidine 
tag.  Purification then followed the protocol stated above for native proteins. 
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2.2  Limited Proteolysis 
 
 
90μg GtgE43-214 was treated with subtilisin protease (Sigma Aldrich) in a 
range of 0.55μg to 10.92μg with 5mM CaCl2 for 20 minutes at 4°C.  The reaction 
was terminated with the addition of 10mM PMSF and SDS loading buffer.  The 
digest of the Rab38V44I/GtgEC45A complex was run under the same conditions; 
however, 34.8μg of complex material was treated with subtilisin ranging from 
0.00174μg to 0.261μg and the reaction allowed to proceed for 30 minutes at 4°C. 
Cleavage products from both reactions were separated by 15% SDS-PAGE, 
transferred to PVDF membrane (Millipore), and stained with SYPRO® Ruby 
protein stain (Sigma Aldrich).  Major protein bands were cut from the membrane 
and sent to the Columbia University Protein Core Facility (New York, NY) for N-
terminal Edman degradation sequencing. 
 
 
2.3  Crystallization and Structure Determination 
 
 
Native GtgE79-214 was crystallized in a hanging drop format at a 10mg/mL 
drop concentration at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, and 0.1M Tris, pH 
7.0.  Selenomethionine-substituted GtgE79-214 was crystallized by two rounds of 
seeding with native crystals at a 10mg/mL drop concentration at 4°C in 0.2M 
Li2SO4, 1.75M (NH4)2SO4, 0.1M Tris, pH 7.0.  Crystals were cryo-protected in 
0.3M LiSO4, 2.5M (NH4)2SO4, 0.1M Tris, pH 7.0 and flash-frozen in liquid nitrogen 
for data collection.  X-ray data was collected at Brookhaven National Synchrotron 
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Light Source (NSLS) Beamline X29, and processed using HKL2000 [79].  
Phasing and initial protein building of the selenomethione-substituted protein was 
done in Phenix using AutoSol [80-83].  Automated building produced a model 
with 133 residues, and the initial model was used subsequently with ARP/wARP 
to build a model with the higher resolution native data [84].  Refinement of this 
model was carried out with REFMAC5 [85, 86] and manual model building was 
done in COOT [87].  TLS refinement [88, 89] was used in the last stages of 
refinement to generate a model spanning residues 80-213 with an R/Rfree of 
19.31%/22.97% (Table 2).  No electron density was observed for residues 79, 
145, 146, 171, 193-199, and 214, so these residues were not modeled into the 
final structure.  98% of the residues fall into the most favored region of the 




2.4  Gel-based Activity Assay 
 
 
The activity assay was performed using Rab38 and GtgE material purified 
as detailed.  GtgE and Rab38 were mixed in a 1:4 molar ratio in the presence of 
10mM CaCl2 and 10mM MgCl2.  End-point assays were performed at 4°C for 30 
minutes and time-point assays were sampled at 4°C, as described in Figure 11C.  
Reactions were stopped with the addition of SDS running buffer and boiled for 10 
minutes before visualization by 15% SDS-PAGE and Coomassie staining.  Time 
point assays were run in triplicate and quantification of GtgE and Rab38 (cleaved 
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and uncleaved) band intensity was performed with ImageJ software [91].  These 
intensities were first normalized against the loading control, GtgE intensity.  
Then, the normalized Rab38 cleavage product intensities were expressed 
relative to the total Rab38 in the reaction, and these cleavage product percent 
values were summed to convey the product formation in terms of the total Rab38 
in the reaction. 
 
 
2.5  Inhibition Assay 
 
 
N-ethylmaleimide, antipain, and chymostatin were solubilized in ethanol, 
water and DMSO, respectively.  5.75μM GtgE-WT was incubated at room 
temperature for 15 minutes with 10mM MgCl2, 10mM CaCl2, and one of the 
following additives: water (positive control), 2.5% ethanol/25% DMSO (delivery 
controls), or an inhibitor (0.25 mM N-ethylmaleimide (Sigma Aldrich), 5mM 
antipain (Sigma Aldrich), and 2.5mM chymostatin (Santa Cruz Biotechnology)).  
5.75μM GtgE-C45A was also incubated at room temperature with water as a 
negative control.  For the leupeptin assay, leupeptin (Sigma Aldrich) was 
reconstituted in water and used in the following concentrations: 10μM, 50μM, 
100μM, 500μM, 1mM, 2mM, and 5mM.  25.3μM Rab38 was then added and the 
reaction was allowed to proceed on ice for 30 minutes.  The reaction was ended 
by the addition of SDS running buffer and boiling.  Results were visualized via 
15% SDS-PAGE and Coomassie staining. 
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CHAPTER 3. RESULTS AND DISCUSSION 
 
 
3.1  Domain Determination 
 
 
Since GtgE lacks significant sequence similarity to proteins of known 
structure, the structural determination of GtgE was necessary in order to gain a 
conclusive understanding of the enzyme’s active site.  Our initial crystallization 
attempts focused on full-length GtgE; however, the full-length construct was not 
amenable to crystallization, so further construct refinement was done based on 
secondary structure predictions and limited proteolysis using subtilisin.  A 
summary of the constructs tested for crystallization can be found in Table 1.  
Constructs with C-terminal truncations past residue 205 were insoluble, and were 
purified under denaturing conditions and refolded using a dialysis-based refolding 
technique (described in Materials and Methods).  Solubility was not affected by 
the N-terminal truncations produced in this work; however, it was noted that GtgE 























Figure 5.  The effect of N-terminal truncations on GtgE activity.  Rab291-177 
is cleaved by full-length GtgE as well as by GtgE18-228, but is not cleaved by 
GtgE29-228.  Rab291-177 that has not been treated with GtgE is in the lane to the far 
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Table 1.  GtgE crystallization constructs.  Yield is given in milligrams of 
protein obtained per liter of cell culture grown. 
 
 
Residue! pI! Soluble! Yield !
(mg/L)!
Active!
1-228! 4.50! Y! 5.3! Y!
18-228! 4.31! Y! 73.4! Y!
29-228! 4.12! Y! 15.6! N!
35-228! 4.12! Y! 14.8!
39-228! 4.17! Y! 12.0!
43-228! 4.17! Y! 15.0!
18-226! 4.31! Y! 7.7!
18-220! 4.29! Y! 65.7! Y!
18-209! 4.19! Y! 18.6! N!
18-195! 4.25! N! 0.9!
18-180! 4.26! N! 0.9!
18-175! 4.30! N! 1.7!
18-170! 4.30! N! 0.9!
29-195! 4.03! N! 5.2!
39-200! 4.08! Y! 1.0!
35-209! 4.00! Y! 6.3!
43-214! 4.08! Y! 13.1!
43-209! 4.04! Y! 3.0!
43-200! 4.08! Y! 1.4!
79-209! 4.05! Y! 1.6!
79-214! 4.11! Y! 9.1! N!
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Several rounds of limited proteolysis using subtilisin were performed as 
detailed until a minimal, crystallizable construct was determined.  Subtilisin 
digestion of GtgE43-228 led to the design of a minimal construct of approximately 
17kD, spanning residues 79-214, which successfully crystallized (Fig. 6).  A 15kD 
construct, roughly residues 79-200, was also identified; however, since GtgE is 
insoluble with C-terminal truncations past residue 205, this construct was not 
pursued.  Edman sequencing of the bands showed that both products began at 

















Figure 6. Subtilisin digestion of GtgE43-214.  Subtilisin concentration shown 
increasing from 0.55μg to 10.92μg from left to right.  Undigested GtgE43-214 is 
shown in the lane at the far left.  The digestion produced two cleavage products: 
















3.2  Crystallization and Data Collection 
 
 
GtgE79-214 was expressed and purified as described.  When purified in 
25mM Tris-HCl, pH 8.0, 250mM NaCl, and 5mM DTT, and at concentrations 
above 30mg/mL, GtgE79-214 exists in both a monomeric and dimeric state.  
Purification conditions that yielded stable, monomeric GtgE79-214 were determined 
(25mM HEPES, pH 8.0, 250mM NaCl, 5mM DTT; 20mg/mL) and used for the 
purification of the crystallized protein product (Fig. 7A).  
 
Ideal crystallization conditions were identified in a 96-well screen using a 
sitting drop format, and crystallization was scaled up into a 15-well hanging drop 
format to obtain well-diffracting crystals for structural determination.  Drops 
contained a 1:1 ratio of reservoir buffer to protein, which was at a 20mg/mL 
concentration.  Crystals grew at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, and 0.1M 
Tris pH 7.0, appearing after 3 days and reaching full size in 1-2 weeks (Fig. 7B).  
The resulting crystals had a bi-pyramidal morphology and were mildly 
birefringent.  Crystals were cryoprotected with 0.3M LiSO4, 2.5M (NH4)2SO4, 























Figure 7.  The purification and crystallization of GtgE79-214.  (A) Purification of 
GtgE79-214 on a Superdex75, 120mL column.  The construct behaves as a 
monomer under the detailed conditions, eluting at 76.39mL.  Lane 1 (far left) 
contains the molecular weight marker, lane 2 is the column load material, and the 
remaining lanes are the fractions corresponding to the elution peak.  (B) Crystals 
of native GtgE79-214 grown at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, 0.1M Tris pH 
7.0 with an initial set-up protein concentration of 20mg/mL.  (C) Crystals of 
selenomethionine-substituted GtgE79-214 were grown under the same conditions 












GtgE’s amino acid sequence does exhibit significant homology to any 
proteins of known structure; therefore, phase determination was carried out 
experimentally via single-wavelength anomalous diffraction (SAD) using 
selenomethionine.  Selenomethionine contains selenium, a heavy atom, in place 
of the sulfur normally present in methionine, and can usually be incorporated into 
a given protein with very little effect on the overall protein structure.  Heavy 
atoms, such as selenium, are able to absorb X-rays and reemit the absorbed 
radiation with an altered phase, producing a measurable difference in intensity 
between two Friedel pair reflections.  This scattering effect, known as anomalous 
scattering, is most prominent when the X-ray wavelength is near the absorption 
edge of the heavy atom, which for selenium is 0.980Å.  SAD enables the location 
of heavy atoms, and when combined with density modification, allows for the 
determination of phases for the entire structure.   
 
For measurable anomalous scattering and subsequent successful phase 
determination, roughly 1 selenium atom per 100 amino acids is required in the 
crystallized protein [92, 93].  GtgE79-214 is 135 residues in length and contains 
three methionines, which equates to 1 selenium atom for every 45 residues, 
making GtgE an ideal candidate for phase determination with selenium as the 
anomalous scatterer.  Selenomethionine-substituted GtgE79-214 was produced as 
detailed.  Crystals of selenomethionine-substituted GtgE79-214 were grown under 
the same conditions as the native crystals through successive rounds of seeding, 
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starting with native crystals.  These crystals had the same morphology as the 
native crystals, but were smaller in size, only growing to roughly two-thirds the 
size of the native crystals (Fig. 7C).  The selenomethionine-substituted crystals 
were cryoprotected using the same cryoprotectant as was used for the native 
crystals and were also flash frozen in liquid nitrogen prior to data collection.  
 
Figure 8.  Diffraction pattern from native GtgE79-214 crystals.  Diffraction data 
was collected at NSLS Beamline X29.  Native crystals diffracted to 1.65Å and 

















































Space group                     ! !P41 21 2 ! ! ! ! !P41 21 2!
Cell Dimensions!
     a, b, c (Å)                     ! !56.181, 56.181, 125.124 ! ! !56.126, 56.126, 125.033!
     α, β, γ (°) ! !        ! !90, 90, 90 ! ! ! ! !90, 90, 90!
Wavelength (Å) ! ! !1.0750 ! ! ! ! !0.9790!
Resolution (Å)      ! ! !50.00 - 1.65 (1.71 - 1.65) ! ! !50.00 – 2.38 (2.47 – 2.38)!
No. of reflections           ! !420901 ! ! ! ! !425153 !!
No. of unique reflections ! !23155 (2428)! ! ! ! !15090 (1550)!
R-merge† ! ! ! !0.072 (0.894)! ! ! ! !0.162 (0.705)!
Mean I/σ(I)                        ! !30.13 (3.2)                               ! !16.45 (4.67)!
Completeness (%)         ! !92.6 (100.0) ! ! ! ! !99.0 (100.0)!
Redundancy ! ! ! !11.2 (11.7) ! ! ! ! !15.3 (15.5)!
Refinement!
Resolution (Å)      ! ! !19.63 - 1.65 (1.693 - 1.65)!
No. of reflections ! ! !21891 (1778)!
R-factor‡                             !0.1931 (0.258)!
R-free‡                                !0.2297 (0.250)!
Number of atoms           !           1129!
     macromolecules        !           957!
     ligands                        !           5!
     water                           !           167!
Amino acid residues             !124!
RMS bonds (Å)              !           0.017!
RMS angles (°)                              1.75!
Average B-factor             !           30.40!
Ramachandran favored (%)          98!
Ramachandran outliers (%)           0!
Statistics for the highest-resolution shell are shown in parentheses.!
R-free value test set size: 5%!
† As defined and calculated by HKL2000!
‡ As defined and calculated by Refmac5!
Native! Selenomethionine-substituted!
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3.3  Overall Structure 
 
 
The structure of GtgE, residues 80-213, was solved to 1.65Å.  Diffraction 
data were collected at Beamline X29 at the National Synchrotron Light Source 
(NSLS) at Brookhaven National Laboratory (BNL) from selenomethionine-
substituted and native protein crystals (Fig. 8).  Both native and 
selenomethionine crystals belonged to the P41212 space group, diffracting to 
2.38Å and 1.65Å, respectively.  The model was built automatically into the SAD 
data with Phenix AutoSol [80, 81], and the initial model was used subsequently 
with ARP/wARP [84] to build a model with the native data (Table 2).  
 
The final structure of GtgE80-213 is comprised of a six-stranded beta-sheet 
that is sandwiched between three helices on one side of the sheet and one helix 
on the other (Fig. 9).  The beta strands are arranged in an antiparallel beta-sheet 
adopting the topology depicted in Figure 9B.  There are three beta hairpins 
connecting beta strand 2 (β2) to β3, β3 to β4, and β4 to β5, and a beta-turn 
located between helix 4 and β6.  The structure contains 167 water molecules and 
124 amino acids, spanning residues 80-213, with an R/Rfree = 0.1931/0.2297 
(Table 2).  No electron density was observed for residues 79, 145, 146, 171, 193-





Figure 9.  The structure of GtgE80-213.  (A) The overall fold of GtgE, residues 
80-213.  Helices shown in red, beta strands shown in blue, and areas without 
observable electron density represented with a dashed line.  His151 and Asp169 
are depicted as sticks in green.  (B) Topology diagram of GtgE, residues 80-213.  
Generated by PDBSum [94].  (C) The secondary structure sequence alignment 
for GtgE, residues 80-213.  There are five helices, numbered and shown in red; 
six beta strands depicted in blue and labeled by their sheets; and active residues, 
His 151 and Asp169, are indicated with a red box.  β-turns are represented by β, 



































LMLIRPS  SECLHAECIVGYDSEVKKVLIYDS NTSPEWQSNIDVYDKLTLAFN!
   CSICGLYYDGVYEP!
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3.3.1  Structural Homologs 
 
 
Structural homologs were identified using the DaliLite v. 3 [95].  Z-scores 
above 2.0 are considered significant, usually corresponding to the presence of 
similar folds [96].  There were 740 hits, largely cysteine proteases, with z-scores 
above 2.0, and of those hits, 23 had a Z-score above 5.0.  The top 20 structure 
hits are summarized in Table 3.  Our structure reveals significant similarity to 
cysteine proteases of Clan CA, namely families C1, C2, and C39 [95].  Clans 
denote evidence of a common ancestry, thus proteins within a clan share a 
common structural fold.  Clan CA proteases share a papain-like catalytic fold 
comprised of 6 beta strands sandwiched between a variable number of alpha 
helices, and function using a catalytic triad.  Two key active residues are a 
cysteine positioned at the beginning of an alpha helix and a histidine located at 
the beginning of beta strand 3.  The third triad member (Asn/Glu for C1; Asn for 
C2; Asp/Glu for C39) is located at the end of beta strand 4, and is responsible for 
the proper orientation of the catalytic histidine [97, 98].  The catalytic core also 
contains a glutamine residue that resides a short distance N-terminal to the 
active cysteine, aiding in the stabilization of the reaction intermediate [97].   
 
Proteins are further categorized into families based on their function 
and/or catalytic residue organization.  In eukaryotes, members of the C1 family 
primarily serve as proteolytic enzymes in the lysosomal pathway [98].  C2 family 
members include the calcium-dependent calpains, which function in a variety of 
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cellular processes, such as signal transduction, apoptosis, and cytoskeletal 
remodeling [98].  The C39 endopeptidases are bacterial proteins that are 
responsible for the maturation of bacteriocin, a secreted bacterial antibiotic 





























Table 3.  Structural homologs of GtgE80-213.  Homologs identified by the 
DaliLite v. 3 Homology Server [95].  Z-scores above 2.0 are considered 















3zua-A! 6.3! 2.5! 142! 83! 12! Alpha-hemolysin 
translocation!
ATP-binding protein!
1df0-A! 6.1! 3.3! 624! 85! 14! M-Calpain!
1u5i-A! 6.0! 3.2! 625! 85! 14! Calpain 2, large subunit 
precursor!
3b79-A! 5.9! 2.4! 125! 77! 8! Toxin secretion ATP-
binding protein!
3k8u-A! 5.5! 2.7! 137! 81! 10! Putative ABC transporter, !
ATP-binding protein!
4d8e-A! 5.4! 3.7! 254! 89! 15! Streptopain!
2bu3-B! 5.3! 3.9! 204! 97! 15! ALR0975 protein!
1mdw-A! 5.3! 3.2! 319! 82! 15! Calpain II, catyalytic 
subunit!
1pvj-C! 5.3! 3.2! 339! 88! 15! Pyrogenic exotoxin B!
1pvj-B! 5.3! 3.2! 339! 88! 15! Pyrogenic exotoxin B!
1pvj-D! 5.3! 3.2! 339! 88! 15! Pyrogenic exotoxin B!
2bu3-A! 5.2! 3.9! 200! 96! 16! ALR0975 protein!
1cv8-A! 5.2! 3.3! 173! 84! 11! Staphopain!
3bba-A! 5.2! 3.3! 246! 88! 15! Interpain A!
2uzj-B! 5.2! 3.6! 249! 88! 15! Streptopain!
3bba-B! 5.1! 3.3! 250! 88! 15! Interpain A!
2uzj-B! 5.1! 3.8! 247! 89! 15! Streptopain!
2ftd-A! 5.1! 3.4! 215! 80! 16! Cathepsin K!
2nga-B! 5.0! 3.5! 318! 84! 14! Calpain 8!
2btw-B! 5.0! 3.9! 210! 95! 16! ALR0975 protein!
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3.4  Identification of the Catalytic Triad  
 
 
GtgE’s overall fold and placement of its active histidine (His151) align best 
to homologs of the cysteine protease superfamily Clan CA (Fig. 10).  His151 was 
identified as an active residue by Spanò, et al. and confirmed through 
mutagenesis, His151Ala, and homolog structural alignment in this work (Fig. 10, 



















Figure 10.  The active site alignment of GtgE80-213 with its structural 
homologs.  GtgE80-213 (purple) with active residues His151 and Asp169; C39 
family member, ComA (PDB: 3K8U, blue) with active residues Cys17, His96, 
Asp112 shown; C2 family member Calpain II (PDB: 1MDW, red) with active 
residues Cys105Ser, His262, Asn286; and C1 family member papain (PDB: 
9PAP, yellow) with active residues Cys(OCS)25, His159, and Asn175. 
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3.4.1  Active Cysteine 
 
 
Our crystal structure did not contain a cysteine in the canonical position, 
nor did it contain any cysteines in proximity to the other active site residues.  In 
addition, the cysteine containing helix present in members of this superfamily 
was not present in the active site.  Since the crystal structure lacks the first 78 
residues of GtgE, we hypothesized that the active site cysteine must be located 
in the missing N-terminal domain.  To confirm this hypothesis, we made point 
mutations (Cys to Ala) of each of the eight cysteine residues in GtgE and tested 
the enzyme’s ability to cleave Rab38.  Cys45 was the only Cys-to-Ala mutation 
that resulted in a loss of activity, and therefore, is the active cysteine of GtgE’s 
catalytic triad (Fig. 11B).  Although Cys45 is missing from our structure, we 
predict, based on the conserved homolog structure, that it resides at the 




3.4.2  Active Aspartic Acid 
 
Based on our structure of GtgE80-213 we were able to narrow down the 
possible identity of the third triad member to two residues: aspartic acid 169 and 
asparagine 172.  Both residues are situated near the end of beta strand 4; 
however, no electron density was observed for the side chain of Asn172, so it 
could not be determined, from the structure alone, which residue was correctly 
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placed to participate in the active site.  Through point mutation, Asp169Ala and 
Asn172Ala, Asp169 was identified as the third triad member, capable of 
significantly decreasing GtgE’s activity; whereas, Asn172Ala does not appear to 











































Figure 11.  The catalytic triad of GtgE.  (A) Mutations (C45A, H151A, D169A) 
to the catalytic triad of GtgE greatly reduce enzyme activity in vitro.  N172A did 
not noticeably affect activity.  (B) The Cys-to-Ala mutation activity profile for 
GtgE.  Of all eight cysteines, only C45A shows a loss of function, indicating that it 
is the active cysteine of GtgE.  (C) Catalytic triad residues (Cys45, His151, and 
Asp169) were mutated to alanines and their cleavage of Rab38 was charted as 
percent of total Rab38 cleaved over time, in minutes.  Standard error of the mean 










































































































































3.4.3  Quantitative Analysis of Catalytic Triad Mutations 
 
To further investigate the effects of alanine mutations to the catalytic triad 
members, GtgE’s cleavage of Rab38 was plotted in terms of the percent of total 
Rab38 cleaved over time (Fig. 11C).  Under the reaction conditions described, 
wild-type GtgE cleaved 36% of Rab38 over the course of 30 minutes with the 
reaction reaching completion after 10 minutes of activity.  Alanine mutations to 
Cys45, His151, and Asp169 resulted in the reduction of GtgE activity by 94%, 
89%, and 72%, respectively, indicating that these residues are key components 
of GtgE’s active site.  
 
3.4.4  Proposed Catalytic Mechanism 
 
Through this work, we have determined that GtgE is a cysteine 
endopeptidase, functioning with a catalytic triad composed of Cys45, His151, and 
Asp169.  Together, these residues are capable of breaking the peptide bond 
between two highly conserved glycine and valine residues located in the Switch I 
region of Rab29, Rab32, and Rab38.  A proposed mechanism for this reaction is 
diagramed in Figure 12. 
 
The reaction is initiated once the Rab substrate enters the active site, 
creating an environment in which the nitrogen (ND1) of His151 depronates the 
thiol of Cys45.  This depronation leads to the nucleophilic attack of the Cys45 
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sulfur on the carbonyl carbon of the glycine.  A thioester linkage between the 
sulfur and the N-terminal section of the Rab substrate is then formed, and the 
nitrogen of the valine depronates the pronated His151 nitrogen (ND1), releasing 
the C-terminal Rab cleavage product and returning His151 to its initial state.  A 
water molecule hydrolyzes the thioester linkage, which liberates the N-terminal 
Rab cleavage product and regenerates Cys45.  Asp169 is not directly involved in 
the proton transfer necessary for catalysis; however, it is required for the proper 












Figure 12.  The proposed reaction mechanism for GtgE.  GtgE functions as a 
cysteine protease to cleave its Rab substrate (Rab29, Rab32, and Rab38) 
between a critical glycine and valine in the Switch I region of these GTPases.  
GtgE uses a catalytic triad of Cys45, His151, and Asp169 to perform this 





































3.4.5  Complete Active Site Construct Design 
 
 
Since our crystallized construct does not contain the active cysteine, we 
sought to crystallize a larger construct that would encompass the entire active 
site.  Previous crystallization screens on larger domains of GtgE proved 
unsuccessful; therefore, we engineered GtgE43-214, the largest minimal domain 
containing all three active residues, based on information obtained from our 













Figure 13.  The alignment of GtgE80-213 with ComA, a C39 family member.  
ComA (PBD: 3K8U, cyan) and GtgE80-213 (purple) with helices labeled (H1, H2, 
etc.) for each and color-coded accordingly.  Active residues for both structures 







There were two disordered loops in the GtgE80-213 structure, so to create a 
construct with a higher crystallization potential, we mutated residues in each loop 
to decrease the surface entropy of the protein and encourage protein-protein 
interactions.  In disordered loop 1, spanning residues 145 to 147, Leu145, 
Ser147, and Glu148 were mutated to alanine.  For disordered loop 2, which 
spans residues 193 to 199, Lys194, Lys196, and Glu198 were mutated to 
alanine.  GtgE43-214 constructs with mutations to loop 1 or loop 2 were screened 
for crystallization separately as well as together, in a GtgE43-214 construct that 
contained mutations in both loop 1 and loop 2.   
 
Through comparison and modeling work between GtgE80-213 and its C39 
family structural homologs, it was evident that GtgE contains a larger loop region 
located directly N-terminal to the start of GtgE80-213.  In the homologs, this loop 
connects an alpha helix to the helix corresponding to residues 83-93 (H1) in 
GtgE80-213 (Fig. 13).  We believe GtgE has a six-residue insertion in this loop, 
roughly equivalent to residues 74-79.  As further evidence that this region is 
loopy and surface exposed, subtilisin digests of GtgE43-214 led to cleavage 
immediately N-terminal to residue 79 (Fig. 6).  A GtgE construct was designed 
with a deletion of residues 74 to 79, and this was tested for crystallization both 
alone and in combination with the loop 1 and loop 2 mutations.  These 
crystallization screens did not yield crystals. 
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3.5  GtgE Inhibition 
 
 
The inhibition of GtgE may serve as a means to alter the host specificity of 
broad-host Salmonellae.  Equipped with an understanding of GtgE’s function at 
the mechanistic level, we were able to identify three small molecules from a 
panel of cysteine protease inhibitors that are capable of inhibiting GtgE function 
in vitro: N-ethylmaleimide, antipain, and chymostatin (Fig. 14A-C).  N-
ethylmaleimide (NEM) covalently modifies cysteine residues, making it the least 
specific, although most potent, of the three inhibitors, showing inhibition at a 1:43 
molar ratio of GtgE to NEM (Fig. 14B).   
 
Antipain and chymostatin are both microbial-derived small peptide 
inhibitors which contain a C-terminal aldehyde that inhibits cysteine proteases by 
forming a hemiacetal adduct with the active thiol [100].  Antipain is bulky in 
structure (Arg-Val-Arg-Phe), and broadly targets cysteine and serine proteases 
(Fig. 14A).  Chymostatin is composed of two phenylalanines, capreomycidine, a 
large residue unique to microbes, and a variable hydrophobic residue (Fig. 14A).  
Exhibiting greater specificity than antipain, chymostatin inhibits papain, 
chymotrypsin, and cathepsins A/B/C/H/L.  Chymostatin was two-fold more potent 
of an inhibitor for GtgE than was antipain, inhibiting GtgE at a molar ratio of 1:435 
GtgE to chymostatin, compared to a molar ratio of 1:870 GtgE to antipain (Fig. 
14B).  Conversely, leupeptin, another microbial-derived inhibitor comprised of 
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residues with relatively small side chains (Leu-Leu-Arg) (Fig. 14A), does not 




















Figure 14.  Inhibition of GtgE.  (A) The structures of cysteine protease 
microbial-derived small peptide inhibitors.  (B) GtgE is inhibited by NEM, 
chymostatin, and antipain.  The reactions with chymostatin and its delivery 
control, DMSO, were performed separately using identical conditions to that of 
the reactions with NEM and antipain; thus, this is indicated with a black line.   
(C) Leupeptin does not inhibit GtgE at the highest concentration that could be 
tested given leupeptin’s solubility.  At a molar ratio of 1:870, GtgE to leupeptin, 
leupeptin did not inhibit GtgE’s ability to cleave Rab38.  The activity of GtgE-
























































The GtgE cleavage site on its Rab29/32/38 substrates is highly conserved 
among these three Rab GTPases, consisting predominantly of hydrophobic 
residues and several residues with bulkier side chains, such as aspartic acid and 
phenylalanine.  We theorize that chymostatin and antipain are more suited to 
inhibit GtgE because they both contain aromatic residues, whereas leupeptin 
does not.  Therefore, these inhibitors are better able to mimic the Rab29/32/38 




3.6  The GtgE/Rab GTPase Complex 
 
 
To investigate the nature of GtgE’s interaction with its Rab GTPase 
substrates, we determined the necessary conditions for stable complex formation 
in vitro for the purposes of crystallization and structure determination.  We initially 
examined complex formation, as verified by an elution peak shift on the size 
exclusion Superdex 200, 120mL column (GE Healthcare), between the 
catalytically inactive GtgEC45A and Rab29, 32, and 38.  Complex stability is 
defined here as the ability of the complex to remain in solution at 4°C for at least 
several days post-purification, and for the appearance of lower molecular weight 
Rab cleavage bands to be minimal.    
 
Rab29 was found to be the least stable in vitro; however, it was found that 
Rab29 could be expressed in larger quantities when expressed with a C-terminal 
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truncation of the last 26 residues, thereby making it possible to perform 
subsequent binding assays using this substrate.  Rab38 was determined to be 
the most ideal of the three candidates in forming a stable complex with GtgEC45A.  
Unlike Rab29 and Rab32, Rab38 did not precipitate during purification and was 
even stable for up to 18 hours at room temperature.  A cleavage band at 
approximately 14kD did appear, as it did during the purification of the other Rabs, 
and could be due to cleavage by a contaminating protease or by residual activity 
of GtgEC45A itself.  The addition of a protease inhibitor cocktail did not prevent this 
cleavage.  
  
Various mutations in both GtgE and Rab29/Rab38 were screened in an 
effort to identify a combination of mutations that would result in a stable complex 
with minimal residual Rab38 cleavage.  These mutations, their ability to form a 
complex, and the long-term stability of the complex are summarized in Table 4.  
The GtgE mutations were initially tested in complex with Rab291-177, and the 



































Mutations in GtgE’s catalytic core were focused on C45A, H151A, double 
mutant C45A and H151A, and double mutant C45A and C48A.  Of these four, 
only the single C45A mutation yielded a stable complex over time.  GtgE-
C45A/C48A formed a complex with Rab291-177, but a significant cleavage band 
appeared during purification.  The double catalytic mutant C45A/H151A also 
formed a complex with Rab291-177, but this complex dissociated during 
purification, possibly because the double mutation disturbed the active site in 
such a way as to decrease GtgE’s ability to tightly grasp its Rab substrate.  



















To examine GtgE’s ability to recognize Rab38 in its GTP-bound (“on”) 
state or its GDP-bound (“off”) state, constitutively active (Q69L) and constitutively 
inactive (S35N) mutations on Rab38 were produced.  The constitutively active 
glutamine to leucine mutation prevents the binding of the GTPase Activating 
Protein (GAP) so that there is no external stimulation of the Rab’s GTPase 
activity [101].  The glutamine residue also plays an important role in GTP 
hydrolysis, forming a hydrogen bond with a water molecule positioned to attack 
the phosphoryl bond of GTP [102].  Since leucine cannot participate in such an 
interaction, the Q69L mutation also inhibits the Rab’s intrinsic rate of GTP 
hydrolysis [101, 103].   
 
The constitutively inactive mutant, serine to asparagine, increases the 
Rab’s affinity for GDP [104].  The inactive mutant retains its ability to bind 
Guanine Nucleotide Exchange Factors (GEFs), but since exchange for GTP does 
not occur, the mutant Rab forms a dead-end complex with its GEF, and 
therefore, is trapped in its ‘off’ state [105].  GtgEC45A binds both Rab38Q69L and 
Rab38S35N with equal affinity, as judged by the ratio of GtgE to mutant and wild-
type Rab38 purified in complex by size exclusion chromatography.  Therefore, 
based on this work, GtgE does not show preference for either Rab conformation, 
and is able to recognize and bind stably to both the constitutively active and 
constitutively inactive Rab38 mutants. 
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We also made various mutations around the GtgE cleavage site on Rab29 
and Rab38 to identify a mutation that led to a decrease in the appearance of 
lower molecular weight Rab products.  Mutations in Gly41 in Rab29 prevented 
complex formation with GtgEC45A, and only one mutation in Rab38, V44I, made a 
significant reduction in the formation of the 14kD cleavage band.  
 
The purification of the GtgEC45A/Rab38V44I complex on the Superdex 200, 
120mL column (GE Healthcare) is shown in Figure 15A.  GtgEC45A elutes at 
89.23mL (Fig. 15B), Rab38V44I elutes at 93.52mL (Fig. 15C), and the complex 
elutes at 88.44mL (Fig. 15A).  Through work with the wild-type complex 
(Rab38/GtgEC45A), it was determined that the complex is most stable at a 
relatively neutral pH (pH 7.5-8.0), a salt concentration of 100mM-250mM sodium 
chloride, 5mM of reducing agent dithiothreitol, and a minimum of 100μM 
magnesium chloride.  The Rab GTPases are not stable without the addition of 
magnesium chloride, as the magnesium ion is necessary for the protein’s stable 
interaction with GTP/GDP.  Complex preparations were performed with an 
excess of magnesium chloride, 5mM MgCl2, and material used for crystallization 
was exchanged into buffer containing 100μM MgCl2.  Additionally, complex 
formation was affected by the method of expression used for the two 
components.  A stable complex was only obtained when Rab38 and GtgEC45A 
were co-expressed on the same plasmid with Rab38 N-terminally His-tagged and 
























Figure 15.  The purification of full-length Rab38V44I and full-length GtgEC45A.  
(A) GtgEC45A and Rab38V44I, in complex, elutes at 88.44mL on a Superdex200, 
120mL column (GE Healthcare).  (B) GtgEC45A elutes at 89.23mL.  (C) Rab38V44I 
elutes at 93.52mL.  Lane 1 (far left) on gels is the molecular weight marker, lane 
2 is the column load material, and the remaining lanes are fractions 




Crystallization screens were carried out with each stable variation of the 
complex that was produced.  The Rab38V44I/GtgEC45A material was subjected to 
limited proteolysis by subtilisin and trypsin to identify minimal constructs for 
crystallization.  The subtilisin digest is shown in Figure 16.  The complex was 














incubated for 30 minutes at 4°C.  There were two main cleavage products at 
approximately 23kD and 19kD.  Edman sequencing of these bands revealed that 
the 23kD product corresponds to full-length Rab38V44I and GtgE18-228, C45A, and 
the 19kD band corresponds to GtgE57-228, C45A.  A robust co-expression of Rab38 
V44I with GtgE18-228, C45A was not possible, yielding low expression levels of mostly 
insoluble GtgE18-228, C45A.  However, a complex between Rab38 and GtgE23-228, 







Figure 16.  Limited proteolysis of the Rab38V44I /GtgEC45A complex.  The 
complex was digested with 1.7ng to 0.261μg of subtilisin protease.  The reaction 
was performed at 4°C for 30 minutes.  Untreated complex material is shown in 




















CHAPTER 4.   CONCLUSIONS 
 
 
Members of the cysteine protease superfamily participate in a diverse 
array of biological pathways.  The conserved active site triad is remarkably 
adaptable to seemingly disparate chemical reactions, functioning within enzymes 
as different as proteases, acetyltransferases, transglutamases, deamidases, and 
deubiqutinases.  The catalytic activity of these enzymes is driven by a 
nucleophilic cysteine thiol and an electron-accepting histidine, and often requires 
a third residue for the proper orientation of this cysteine-histidine pair.  
Superfamily members share a conserved overall fold, but differ in the placement 
of catalytic triad residues within their canonical active site.   
 
Interestingly, a sizeable portion of characterized bacterial T3SS effector 
proteins belong to the cysteine protease superfamily, utilizing this cysteine-
powered catalytic core to manipulate the host’s cellular processes in a variety of 
ways.  For example, Escherichia coli encoded Cif, functions as a deamidase, 
using a Cys-His-Gln catalytic core to deamidate a critical glutamine in the 
ubiquitin-like NEDD8 protein [106].  Through binding to and deamidating NEDD8, 
Cif effectively prevents the E3 ligase activity of neddylated CRL complexes, 
resulting in cell cycle arrest, formation of stress fibers, and host apoptosis [107-
112].  Another cysteine protease effector, Yersinia pestis Yop J, employs its His-
Glu-Cys triad to acetylate serine and threonine residues on MAPK kinases and 
the IκB kinase complex, inhibiting both MAPK signaling and activation of the 
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NFκB pathway, respectively [113, 114].  YopJ’s catalytic activity ultimately leads 
to the inhibition of innate and adaptive immunity responses and to the induction 
of cell death [113, 115-117].  In addition, S. typhimurium produces a 
deubiquitinase, SseL, which functions using a His-Asn-Cys triad to remove K63-
linked ubiquitin chains from SCV-associated aggregates that are targeted for 
autophagic degradation [118, 119].  In this manner, SseL decreases the 
autophagic flux within the host, consequently contributing to down modulation of 
NF-κB-dependent cytokine production and macrophage-delayed cytotoxicity 
[118-121]. 
 
GtgE is the newest addition to this growing list of bacterial effector 
cysteine proteases.  Produced by S. typhimurium, GtgE cleaves its Rab GTPase 
substrates, Rab29, Rab32, and Rab38, preventing the delivery of antimicrobial 
agents to the SCV; thereby, subverting one facet of the host’s defense 
mechanism.  In this manner, GtgE contributes to the ability of broad-host strains 
of Salmonella to maintain a diverse repertoire of host species.  Our crystal 
structure of GtgE80-213 firmly establishes that GtgE is a cysteine protease of Clan 
CA utilizing a catalytic triad of Cys45, His151, and Asp169.  Biochemical studies 
with mutations in the active site residues show dramatic loss of activity against 





The inhibition of GtgE may serve as a means to alter the host specificity of 
broad-host Salmonellae.  Equipped with an understanding of GtgE’s function at 
the mechanistic level, we were able to identify three small molecules from a 
panel of cysteine protease inhibitors that are capable of inhibiting GtgE function 
in vitro: N-ethylmaleimide, antipain, and chymostatin.  All of these compounds 
target the active thiol; however, due to their more specific inhibition, antipain and 
chymostatin are best suited to provide the foundation for more targeted inhibitor 
design.  Chymostatin and antipain are bulkier microbial-derived small peptide 
inhibitors, which more closely mimic the cleavage site of GtgE’s Rab GTPase 
substrates.  Conversely, leupeptin, a microbial-derived inhibitor comprised of 
residues with relatively small side chains, targets the active thiol in the same 
manner as chymostatin and antipain, but does not inhibit GtgE. 
 
Our work with the GtgE/Rab GTPase complex has led to the identification 
of in vitro conditions that maintain long-term stability of the complex.  Of GtgE’s 
substrates, we have shown that Rab38 is the most amenable to in vitro work and 
with additional purification optimization, the GtgE/Rab38 complex may prove to 
be the best option for crystallization of the complex.  Through obtaining a 
structure of GtgE in complex with its substrate, we hope to characterize GtgE’s 
interaction and possible recognition of its substrate, providing a more thorough 
understanding of how GtgE functions in vivo.    
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Since Rab GTPases undergo significant structural changes depending on 
whether they are bound to GDP or GTP, it is imperative to crystallization success 
that the Rab protein under study adopts a homogenous conformation.  We 
attempted to address this by making constitutively active, GTP-bound 
conformation, and constitutively inactive, GDP-bound conformation, mutations to 
Rab38.  We did not find a measurable difference in complex formation or stability 
between GtgE and the constitutively active or inactive mutant of Rab38, and 
neither complex yielded crystals.  Another method that may prove more useful in 
creating Rab homogeneity is to chemically induce nucleotide loading of either 
GDP or a non-hydrolyzable analog of GTP, such as Gpp(NH)p.  This method 
may better mimic the GDP/GTP-bound conformations of Rab in vitro, perhaps 





















APPENDIX I.  SALMONELLA INVASION PROTEIN C 
 
 
AI.1  Introduction 
 
 
 Salmonella Invasion Protein C (SipC/SspC) is encoded on Salmonella 
pathogenicity island 1 and is secreted by the T3SS1 [122].  Expression and 
secretion of SipC is controlled by its chaperone, Salmonella invasion chaperone 
A (SicA) [123, 124].  SipC plays a critical role in Salmonella infection, serving as 
both a translocase and an effector protein, and is necessary for host invasion 
[125, 126].  SipC is a 42kD protein with one predicted transmembrane domain 


















Figure 17.  SipC and host cell invasion.  SipC is a 409 residue effector and 
translocase protein, and is predicted to oligomerize with SipB to form the 
translocon pore in the host cell membrane.  The N-terminal 120 residues of SipC 
extend into the host cytosol where they function in actin bundling, while the C-






























Shigella flexneri invasion plasmid antigen C (IpaC) is highly homologous 
to SipC, sharing 34% amino acid identity and 54% similarity with SipC [127].  
IpaC and SipC share a significant sequence homology in their respective 
hydrophobic domains and C-terminal effector domain, and both are known to 
interact with actin [128].  A key difference in the way Shigella and Salmonella 
infect cells is that Salmonella remains within the SVC after host entry, while 
Shigella escapes into the host cytoplasm [128].  SipC and IpaC appear to be 
important players in this difference in infection behavior, although the exact 
cause of this difference remains unknown [128].  
 
 
AI.1.1  The Translocon 
 
 
SipC oligomerizes with Salmonella Invasion Protein B (SipB), another 
translocase protein, to form the translocon pore in the host cell membrane.  The 
two proteins have been shown to associate in vitro [30], but it is not understood 
how they are inserted into, and associate within, the membrane.  SipC is not 
detected in the host cell membrane in the absence of SipB, suggesting that SipC 
is dependent on SipB for membrane insertion [25, 127].  It is unclear whether 
SipB and SipC oligomerize into a ring structure prior to membrane insertion, but 
complex formation between SipC and SipB is essential for their insertion into the 
membrane, and a domain of SipC, residues 340 to 409, is required for its 
interaction with SipB [129].  Once inserted into the membrane, SipC is 
hypothesized to assume a hairpin-like formation, such that its central 
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hydrophobic domain resides within the plasma membrane while its N- and C-
terminal effector domains extend into the host cell cytoplasm (Fig. 17) [25].     
 
 
AI.1.2  SipC: N-terminal Domain 
 
 
Functioning as a Salmonella effector protein, SipC participates in the 
rearrangement of the host’s actin cytoskeleton, aiding in Salmonella’s initial 
uptake by the host.  Actin rearrangement by SipC appears to be enhanced by the 
action of another Salmonella invasion protein, SipA, suggesting that SipC 
cooperates with SipA in vivo [130].  Both SipC and SipA appear to bind directly to 
actin and influence filament dynamics independently of host cell components 
[30].  The N-terminal domain of SipC, spanning residues 1 to 120, bundles actin 
filaments in a 1:1 SipC to actin filament molar ratio in vitro [30].  
 
Actin is a 42kD globular protein that serves as the building block for 
microfilament formation in eukaryotic cells.  There is a large variety of eukaryotic 
actin binding proteins that help to tightly regulate microfilament dynamics inside 
the cell.  Monomeric actin, known as G-actin, polymerizes to form long, 
filamentous, double-helical polymers, called F-actin.  Proteins responsible for 
actin bundling, such as the N-terminal domain of SipC, are able to group together 
F-actin strands into bundles (Fig. 17).  These bundles function primarily in 
maintaining the overall cell structure; allow for force generation; and are also 
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important for phagocytosis [131, 132].  Through actin bundling, the N-terminal 
domain of SipC stimulates host phagocytosis and uptake of the Salmonella cell.  
 
 
AI.1.3  SipC: C-terminal Domain 
 
 
The C-terminal domain of SipC, residues 200 to 409, nucleates actin 
polymerization in vitro (Fig. 17) [30].  Since the G-actin concentration inside the 
cell is kept below the critical concentration, the concentration above which G-
actin polymerizes, the action of actin-nucleating proteins, such as SipC, is 
necessary for actin polymerization [33].  Actin polymerization follows three 
distinct phases: lag phase, filament growth, and steady state (Fig. 18).  
Nucleation begins during the lag phase and continues until approximately 45% of 
the actin is polymerized [133].  During filament growth, filaments polymerize from 
nucleating centers, and a steady state is achieved once the concentration of 
monomeric actin drops to the critical concentration causing polymerization to 
cease [133].  Proteins that nucleate actin polymerization increase the number of 
nucleating centers; therefore, decreasing the length of the lag phase, enabling 
polymerization to begin sooner, and steady state to be achieved faster, than with 
actin alone.  By nucleating actin polymerization, the C-terminal domain of SipC 
enables Salmonella to exploit host actin, ultimately leading to the internalization 

























Figure 18.  Actin polymerization.  The polymerization of actin occurs in three 
stages: lag phase, filament growth, and steady state.  When a nucleating protein 





SipC has an activity range similar to that of the Arp 2/3 complex, which is 
considered to be a relatively weak nucleator in vitro [30, 134].  Thus far, several 
studies have investigated the actin polymerization ability of SipC’s C-terminal 
domain, and have found that, in order to function in vitro, this domain 
multimerizes via contact points located between residues 201 to 220 [135].  
Through in-frame deletion/insertion mutations, residues 201 to 220 were also 
found to be essential for actin nucleation, while residues 321 to 409 were 













Two eukaryotic proteins, cytokeratin 8 and Exo70, are believed to interact 
with the C-terminal domain of SipC.  Yeast two-hybrid experiments with HeLa cell 
cDNA identified cytokeratin 8, a 54kD intermediate filament protein, as a potential 
binding partner of SipC [25].  Cytokeratin 8 is comprised of three domains: a non-
helical N-terminal domain, an alpha helical rod domain, and a non-helical tail [25].  
In this yeast two-hybrid screen, SipC was found to interact with a C-terminal 
segment of cytokeratin 8, spanning roughly two-thirds of the second coil in the 
rod domain in addition to the entire tail domain [25].  The central alpha helical 
domain forms heterodimers with cytokeratin 18 to assemble into dynamic 
filaments that are approximately 10nm in diameter and extend from the nucleus 
to the plasma membrane [137].  Mutations in the C-terminal effector domain of 
SipC disrupted the interaction between SipC and cytokeratin 8, suggesting that 
SipC directly interacts with this filament protein and may utilize this interaction to 
influence the cytoskeletal structure of the host [25].    
 
A study by Nichols, et al. found that the C-terminal domain of SipC is 
sufficient to cause the co-precipitation of endogenous Exocyst Complex 
Component 7 (Exo70, EXOC7) from HeLa cell lysate [138].  Exo70 is one of eight 
exocyst complex proteins that, together, mediate the docking and fusion of 
exocytic vesicles with the plasma membrane.  Exo70 is an 84kD protein 
composed of three helical domains, termed the N, M, and C domains [139].   
Exo70 interacts with several Sec proteins (Sec6, Sec8, Sec10, and Sec15), as 
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well as Arpc1 and numerous small GTPases to target and tether exocytic 
vesicles to the plasma membrane in preparation for SNARE-mediated fusion 
[139, 140].  Through its interplay with Arpc1, a subunit of the Arp2/3 complex, 
Exo70 stabilizes actin reorganization at the plasma membrane [141].  SipC is 
capable of binding Exo70 in its unbound state as well as when it is assembled 
into the exocyst complex [138].  SipC’s interaction with Exo70 serves as another 
means for Salmonella to gain access to the host actin cytoskeleton, enabling the 
bacteria to encourage its own internalization through host phagocytosis.   
 
As an effector protein, SipC is able to interact with host actin both directly, 
through its N- and C-terminal domains, and indirectly, via its interaction with 
cytokeratin 8 and Exo70.  Despite this functional characterization, it is difficult to 
predict how SipC carries out actin rearrangement because the effector lacks 
primary sequence homology to other known eukaryotic actin binding proteins 
[130].  Our aim was to provide structural insight into how this key component of 
Salmonella invasion performs its various effector roles by obtaining the X-ray 












AI.2   Materials and Methods 
 
 
AI.2.1  Protein Expression and Purification 
 
 
SipC1-120, SipC1-120(7+), and SipC5-120 were cloned between the SalI and 
NotI restriction sites in a modified pGEX4 vector (GE Healthcare), containing a 
rhinovirus 3C protease cleavage site C-terminal to GST, and protein was 
expressed in E. coli BL21(DE3) cells for 16 hours at 21°C with 1mM IPTG.  Cells 
were lysed by high-pressure homogenization into lysis buffer (50mM Tris-HCl, pH 
8.0, 200mM NaCl, and 10mM DTT).  Lysate was centrifuged for 40 minutes at 
16,000rpm and supernatant was first passed over a Q-sepharose column (GE 
Healthcare) that was pre-equilibrated in lysis buffer.  Q-sepharose flow-through 
was then run over a glutathione-sepharose column (GE Healthcare) pre-
equilibrated with lysis buffer.  The column was washed with 50mM Tris-HCl, pH 
8.0, 500mM NaCl, and 10mM DTT, and protein was eluted from the column with 
50mM Tris-HCl, pH 8.0, 200mM NaCl, 10mM DTT, and 10mM glutathione.  
Eluted protein was dialyzed for 16 hours at 4°C with in-house prepared 6xHis-
rhinovirus 3C protease into 50mM Tris-HCl, pH 8.0, 150mM NaCl, and 5mM 
DTT.  After dialysis, the protein was passed over a NiNTA column (Qiagen) to 
remove the histidine-tagged 3C protease.  In order to separate free GST from 
untagged SipC1-120, the material was diluted with 50mM Tris-HCl, pH 8.0, 5mM 
DTT to a NaCl concentration of 50mM NaCl, and was then loaded onto a Source 
Q column (GE Healthcare) that was pre-equilibrated in 50mM Tris, pH 8.0, 5mM 
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DTT.  The Source Q column was then washed with 50mM Tris-HCl, pH 8.0, 5mM 
DTT and the bound proteins, free GST and SipC1-120, were eluted from the 
column separately using a salt gradient of 0-100% NaCl, run over 160 minutes.  
Free GST eluted with about 100mM NaCl and SipC1-120 eluted at approximately 
300mM NaCl.  SipC1-120 was then run over a 120mL Superdex 75 column (GE 
Healthcare) into 50mM Tris-HCl, pH 8.0, 150mM NaCl, and 5mM DTT.  Peak 
fractions were collected and concentrated using a 3kD Amicon Ultra centrifugal 
concentrator (Millipore), and loaded onto a 25mL Superdex 200 column (GE 
Healthcare) into a final buffer containing 25mM Tris-HCl, pH 8.0, 150mM NaCl, 
and 2mM DTT. 
 
SipC1-120 was also cloned into a modified pCDF-Duet-1 vector (Novagen) 
between the SalI and NotI restriction sites.  Protein was expressed in E. coli 
BL21(DE3) cells at 21°C with 1mM IPTG for 16 hours.  Cells were lysed with 
high-pressure homogenization into 50mM Tris-HCl, pH 8.0, 300mM NaCl, and 
lysate was centrifuged at 16,000rpm for 40 minutes.  The resulting pellet was 
resuspended in 6M urea, 0.5M NaCl, and 20mM Tris-HCl, pH 8.0, and 
centrifuged again at 16,000rpm for 40 minutes.  The supernatant was applied to 
NiNTA resin (Qiagen) that had been equilibrated in the resuspension buffer.  The 
column was washed with 6M urea, 0.5M NaCl, 30mM imidazole, and 20mM Tris-
HCl, pH 8.0.  Protein was eluted with 6M urea, 0.5M NaCl, 500mM imidazole, 
and 20mM Tris-HCl, pH 8.0.  Work was carried out at room temperature. 
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SipC1-120 was refolded via dialysis refolding at 4°C with protein at 0.2 
mg/mL as detailed in section 2.1.1.  6xHis-rhinovirus 3C protease was added 
during the final stage of dialysis to remove the histidine tag, and the 3C protease 
and cleaved histidine tag were separated from SipC1-120 via a passage over a 
NiNTA column, and SipC1-120 was then further purified over a 120mL Superdex 75 
column (GE Healthcare) and 25mL Superdex 200 column (GE Healthcare) as 
described above.  
 
SipC200-409 and all other SipC C-terminal domain constructs were cloned 
into a modified pCDF-Duet-1 vector (Novagen) between the SalI and NotI 
restriction sites.  Protein was expressed in E. coli BL21(DE3) competent cells 
with 1mM IPTG at 21°C for 16 hours.  Cells were lysed via high-pressure 
homogenization into lysis buffer (50mM HEPES, pH 7.5, 300mM NaCl, and 5mM 
imidazole).  Lysate was centrifuged for 40 minutes at 4°C and 16,000rpm.  
Supernatant was passed over a NiNTA column (Qiagen) pre-equilibrated in lysis 
buffer at 4°C.  The column was washed with 50mM HEPES, pH 7.5, 300mM 
NaCl, 30mM imidazole, and protein was eluted with 50mM HEPES pH 7.5, 
300mM NaCl, 250mM imidazole.  Eluted protein was dialyzed with 6xHIs-
rhinovirus 3C protease for 16 hours at 4°C against 25mM HEPES, pH 7.5, 
200mM NaCl, and 5mM DTT.  The protein was then run over a NiNTA column 
(Qiagen) to remove the histidine tag and 3C protease.  Final purification was 
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done on a 120mL Superdex 75 column (GE Healthcare) into 25mM HEPES, pH 
7.5, 200mM NaCl, and 5mM DTT. 
 
M. musculus Exo701-653 and Exo7085-653 (mExo70) (Source Bioscience) 
were inserted between the SalI and NotI restriction sites of a modified pCDF-
Duet-1 vector (Novagen) containing a hisitidine-NusA tag and rhinovirus 3C 
protease cleavage site.  Purification of mExo70 was performed according to the 
purification scheme described for SipC C-terminal domain constructs, except that 
buffers were made with 25mM Tris-HCl, pH 8.0 and the final purification step was 
done on a 120mL Superdex 200 column (GE Healthcare) in 25mM Tris-HCl, pH 
8.0, 200mM NaCl, and 5mM DTT.  Both mExo1-653 and mExo85-653 eluted as 
monomers under these conditions.   
 
To co-express mExo7085-653 with SipC200-409, SipC200-409 was cloned into 
the second cloning site of a modified NusA-containing pCDF-Duet-1 vector 
(Novagen) (described above) between the NdeI and XhoI restriction sites.  
Purification of the complex was carried out in the same manner as for mExo70 
alone, using buffers containing 25mM Tris, pH 8.0.  To further probe for complex 
stability, the elution from NiNTA resin (Qiagen) was applied to a 120mL Superdex 
200 column (GE Healthcare) in 25mM Tris pH, 8.0, 200mM NaCl, and 5mM DTT.  
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S. typhimurium SpvB was purified as described by Margarit, et al. [142].  
Briefly, SpvB was histidine-tagged and purified using standard NiNTA procedures 
and protein was eluted in buffer containing 50mM Tris-HCl, pH 8.0, 300mM NaCl, 
250mM imidazole.  The final stage of purification was performed on a 120mL 
Superdex 75 column (GE Healthcare) into 10mM Tris-HCl, pH 8.0, 100mM NaCl, 
and 2mM DTT.   
 
 
AI.2.2  Limited Proteolysis 
 
 
Histidine-tagged SipC200-402 was subjected to limited proteolysis using 
subtilisin protease (Sigma Aldrich).  11.5μg of SipC200-409 was incubated with 
3.45ng to 11.5ng of subtilisin and 5mM CaCl2 for 30 minutes at 4°C.  In a similar 
reaction, 8.05μg of SipC200-330 was treated with 48.3ng to 0.483μg of trypsin 
(Sigma Aldrich) and 5mM CaCl2 for 30 minutes at room temperature.  The 
reactions were terminated by the addition of 10mM PMSF and SDS running 
buffer.  Samples were boiled and run on 15% SDS-PAGE and transferred to 
PDVF membrane (Millipore) for Edman sequencing by the Rockefeller University 
Proteomics Resource Center (New York, NY). 
  
 
AI.2.3  Reductive Methylation of Lysine Residues 
 
 
The lysine residues of SipC200-409, SipC200-295, SipC200-290, and SipC195-278 
were reductively methylated using a protocol adapted from Rayment [143].  The 
! 72!
SipC constructs were used in a concentration range of 0.1-0.5mg/mL in a 2mL 
volume and were in a buffer containing 25mM HEPES, pH 7.5, 200mM NaCl, and 
5mM DTT.  40mM dimethyl-amine-borane (DMAB, Sigma Aldrich), prepared in 
water, and 80mM methanol-free formaldehyde (Polysciences, Inc.), prepared in 
water, were added to SipC in a falcon tube.  The tube was wrapped in aluminum 
foil and allowed to incubate at 4°C for 2 hours with gentle mixing.  An additional 
40mM DMAB and 80mM formaldehyde were added to the SipC methylation 
reaction and the reaction was again incubated, gently mixing, at 4°C for 2 hours.  
5mM DMAB was added to the sample, and the reaction was slowly shaken for 16 
hours at 4°C.  250mM ammonium sulfate was then added to the sample to end 
the methylation reaction.  As a final purification step, and to confirm successful 
methylation, SipC samples were run over a 120mL Superdex 75 column (GE 
Healthcare) into 25mM HEPES, pH 7.5, 200mM NaCl, and 5mM DTT. 
 
 
AI.2.4  Crystallization 
 
 
Crystallization screens with SipC200-295 were performed in a 96-well sitting 
drop format using approximately 5mg/mL protein in a 1:1 ratio with reservoir 
buffer to a total volume of 2μL.  Spherulite formation was observed at room 
temperature in a wide range of different conditions, though mostly at a relatively 
neutral pH.  Spherulite hits were globular with a smooth surface.  
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The SipC195-278 crystal screen set-up was analogous to that used for SipC200-295, 
however, the 2μL sitting drops contained 16mg/mL protein in a 1:1 ratio with 
reservoir buffer.  Spherulite formation was seen at room temperature and at 4°C 
predominantly in conditions containing low molecular weight PEGs (PEG 2000-
5000).  Reductively methylated SipC195-278 was also tested for crystallization 
under the same screening conditions used for native SipC195-278, and spherulites 
with thicker needle-like extensions were obtained in 0.1M sodium acetate pH 4.6, 
2M ammonium sulfate. 
 
AI.2.5  SipC and Ribosylated Actin 
 
 
Rabbit skeletal muscle actin (Cytoskeleton, Inc.) was ribosylated as 
detailed by Margarit, et al. [142].  The ribosylation reaction contained 1mg of 
actin, 100ug purified SpvB, and 200μM NAD in a buffer containing 5mM Tris-HCl, 
pH 8.0, 0.2mM ATP, 0.2mM CaCl2, and 2mM DTT to a final volume of 1mL.  The 
reaction was incubated at 4°C for 16 hours with gentle mixing.  100μg SpvB in a 
polymerization buffer with a final composition of 50mM KCl, 2mM MgCl2, 0.2mM 
ATP was added to the reaction and the mixture was incubated at room 
temperature for 2 hours.  The reaction was then centrifuged at 100,000xg for 1 
hour at 4°C and the supernatant was further purified on a 120mL Superdex 75 
column (GE Healthcare) into 5mM Tris-HCl, pH 8.0, 0.2mM CaCl2, 0.2mM ATP, 
100mM NaCl, and 2mM DTT.  Ribosylated actin eluted as a monomer at 
60.18mL.  
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Purified SipC200-330 (in 25mM HEPES, pH 7.5, 250mM NaCl, 5mM DTT) 
was mixed with ribosylated actin in a 1:1 molar ratio, SipC to actin.  The binding 
reaction was carried out in the presence of 150mM NaCl at 4°C for 16 hours with 
gentle mixing.  The reaction was then run over a 120mL Superdex 75 column 
(GE Healthcare) in 25mM Tris-HCl, pH 8.0, 0.2mM CaCl2, 0.2mM ATP, 150mM 
NaCl, and 2mM DTT. 
 
 
AI.2.6  Actin Polymerization Assay 
 
 
Our actin polymerization assay protocol was based on that detailed by 
Cytoskeleton, Inc. (Denver, CO) and Machesky, et al. [144].  Pyrene-actin 
(Cytoskeleton, Inc.) was diluted to 0.45mg/mL using G-buffer (5mM Tris-HCl, pH 
8.0, 0.2mM CaCl2), 0.2mM ATP, and 1mM DTT, and allowed to sit 1 hour on ice.  
The pyrene-actin was then centrifuged at 14,000rpm at 4°C for 30 minutes, and 
the supernatant, containing monomeric pyrene-actin, was removed for use in 
subsequent experiments.  10μM of unlabeled actin (Cytoskeleton, Inc.) 
reconstituted in G-buffer was incubated at room temperature for 60 minutes to 
induce filament formation.  Arp2/3 was diluted to 0.3mg/mL in G-buffer prior to 
the start of the reaction. 
 
The assay was performed in a black-bottom 96-well plate (Sigma Aldrich) 
at room temperature.  Each reaction was performed in a 300μL reaction volume.  
200μL of P-buffer (7.5mM Tris-HCl, pH 8.0, 75mM KCl, 3mM MgCl2, and 1.5mM 
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ATP) was aliquoted into each well.  0.3μM of pre-incubated unlabeled actin in G-
buffer was added to the reaction, followed by SipC200-409 (0.5μM, 1μM, 2.5μM) in 
25mM Tris, pH 8.0, 250mM NaCl, and 5mM DTT, and finally, 0.8μM monomeric 
pyrene-actin in G-buffer was added to the reaction.  The reaction was shaken 
initially to mix and shaken again before each time point was taken.  Time points 
were taken every 30 seconds for 40 minutes.  Excitation was measured at 365nm 
and emission was measured at 407nm.  Arp2/3 (Cytoskeleton, Inc.) together with 
















AI.3  Results and Discussion 
 
 
AI.3.1  SipC N-terminal Domain 
 
 
The N-terminal domain of SipC, spanning residues 1 to 120, was found to 
be either insoluble or unstable in most of the purification schemes examined.  
Purification attempts focused on the following constructs: SipC1-120, SipC5-120, and 
a full construct with an additional random seven residues, LERPHRD, inserted 
after residue 120, denoted SipC1-120(7+).  The SipC5-120 construct was identified by 
M. Lilic as a potential minimal construct through limited proteolysis with subtilisin 
protease (Sigma Aldrich).  GST-tagged SipC1-120 and SipC5-120 were insoluble 
(Fig. 19A); however, SipC1-120(7+) was partially soluble and purified material could 
be concentrated to 0.67mg/mL before precipitation would occur.  This construct 
was also sensitive to salt concentration, and would precipitate under low NaCl 
(<100mM NaCl) conditions. 
 
Histidine-tagged SipC1-120 was also partially soluble and the protein was 
amenable to purification under denaturing conditions and subsequent dialysis-
based refolding (Fig. 19A).  Using these methods, SipC1-120 was purified with a 
total yield of 0.7mg of protein per liter of cell culture grown (Fig. 19B).  Crystal 
screens were set-up using refolded SipC1-120 at the highest concentration 



































Figure 19.  Purification of the N-terminal domain of SipC.  (A) The constructs 
tested for solubility and stability are listed along with their respective solubility 
and yield.  (B) The final purification step for refolded SipC1-120 was done on a 
25mL Superdex 200 column (GE Healthcare).  SipC1-120 runs as a trimer, eluting 
at 15.78mL.  Lane 1 (far left) contains the molecular weight marker, lane 2 is the 
column load material, and the remaining lanes are the fractions corresponding to 

























His-SipC(1-120)! Partially! 0.7 mg/L!
His-SipC(5-120)! No!
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AI.3.2  SipC C-terminal Domain 
 
 
AI.3.2.1  Domain Determination and Purification 
 
 
Our initial SipC C-terminal domain construct spanned residues 200 to 409, 
as this was the domain defined in the literature.  This construct was purified with 
an N-terminal histidine tag as described, and was further purified by size 
exclusion chromatography using a Superdex 75 column (GE Healthcare) with a 
120mL column volume into 20mM HEPES, pH 7.5, 200mM NaCl, and 5mM DTT 
(Fig. 20).  Purification using buffers of varying pH were also examined.  SipC200-
409 was most stable in a 6-8 pH range, and purification in Tris-HCl, pH 8.0, 
HEPES, pH 7.5, bis-tris-propane, pH 6.8, and MES, pH 5.8 showed similar 
protein yields and long-term stability.  SipC200-409 showed significant precipitation 
when purified in acetate buffer at pH 4.6.   
 
The histidine tag used to purify the SipC200-409 domain was not cleavable 
by 3C protease, most likely due to the construct folding in such a way as to 
obscure the cleavage site.  Therefore, SipC200-409, shown in Figure 20A, contains 
the N-terminal histidine tag and runs approximately 7kD larger than it would 
without the tag.  The His-SipC200-409 construct elutes at 50.18mL, running as a 
tetramer, on a 120mL Superdex 75 column (GE Healthcare).  A characteristic 
banding pattern, consisting of three predominant lower molecular weight bands, 
elutes at 57.49mL and was observed in the later stages of purification for the full-
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length C-terminal domain (Fig. 20A).  This cleavage may be due to activity of 














Figure 20.  The purification of the C-terminal domain of SipC.  (A) Histidine-
tagged SipC200-409 was purified on a 120mL Superdex 75 column into 25mM 
HEPES, pH 7.5, 200mM NaCl, and 5mM DTT.  The full-length construct elutes at 
50.81mL, and the characteristic cleavage products elute at 57.49mL.  Lane 1 (far 
left) contains the molecular weight marker, lane 2 is the column load material, 
and the remaining lanes are the fractions corresponding to the elution peak.  (B) 
The C-terminal domain constructs that were produced and screened for 
crystallization.  Yields are estimates based on comparison to protein of known 
concentration by SDS-PAGE because the C-terminal domain of SipC does not 
contain enough aromatic residues to contribute to an accurate UV absorbance, or 





















195-400! 23! 9.2! 0.75 !
195-295! 10.6! 9.2!
195-278! 8.8! 9.3! 1.33!
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Limited proteolysis using subtilisin on native SipC200-409 and denatured and 
refolded SipC200-409 proved unsuccessful in determining a minimal construct (Fig. 
21A), so the cleavage products present during purification were sent to the 
Columbia University Protein Core Facility (New York, NY) for Edman sequencing.  
N-terminal sequencing indicated that cleavage was occurring C-terminally, 
defining constructs starting at residue 200 and ending at residue 360, 330, or 320 
(Fig. 21B).  C-terminal truncations were estimated based on the molecular weight 
of the cleavage products.  This information, combined with secondary structure 
predictions, led to the construction and purification of SipC200-374 and Sip200-320.  
Constructs with various N-terminal starts, at residue 180, 190 and 195, were 
screened as well; however, only those beginning with residue 195 were screened 
for crystallization.  In addition to the constructs listed in Figure 20B, denatured 
and refolded SipC200-409 and SipC195-400, as well as reductively methylated 
SipC200-409, SipC200-295, SipC200-290, and SipC195-278 were tested for crystallization 













Figure 21.  Limited proteolysis of the SipC C-terminal domain.  (A) The 
subtilisin digestion of His-SipC200-409 was performed at 4°C for 30 minutes using 
3.45ng to 11.5ng of subtilisin and 11.5μg of SipC.  (B) His-SipC200-409 cleavage 
products appeared during purification, and C-terminal cleavage was determined 
via Edman sequencing.  Corresponding truncations are shown in red.  (C) 
SipC200-330 was treated with trypsin.  The band sent for Edman sequencing is 
indicated in red.   
 
 
Upon removal of the C-terminal 79 residues for the SipC200-330 construct, 
3C protease was able to access the cleavage site and the histidine tag was 
removed.  This suggests that the C-terminus of SipC200-409 was folded towards 
the N-terminus of the construct and restricted 3C protease’s access to the 
cleavage site.  A trypsin digest of SipC200-330 revealed an additional C-terminal 

























which was estimated based on molecular weight of the cleavage product and the 
location of trypsin cleavage sites (C-terminal to arginine and lysine residues) (Fig. 
21C).  Crystallization trials were set-up with constructs in as high a concentration 
as could be obtained, usually between 2-8mg/mL.  Higher concentrations could 
be attained with the shorter SipC C-terminal domain constructs, and SipC195-278 
could be concentrated to 16mg/mL.   
 
We hypothesized that the instability of SipC could stem from exposed 
membrane-associated regions still potentially present in our constructs.  In an 
effort to mask these areas, we investigated whether the addition of 1M guanine 
HCl or 1% octyl glucoside (w/v) could enable a higher concentration of SipC200-330 
to be achieved.  We found that 1% octyl glucoside (w/v) allowed for the 
concentration of SipC200-330 to roughly 1.5 times greater than that of the material 
concentrated in the presence of 1M guanine HCl and approximately 2 times 
greater than material without either additive, suggesting that the addition of a mild 
detergent may aid in purification of the SipC C-terminal domain. 
 
 
AI.3.2.2  Crystallization 
 
 
SipC200-295 was the largest construct tested that produced crystalline 
growth in crystallization trials (Fig. 22).  The purification of SipC200-295 was 
performed as described, and protein eluted as a tetramer on a 120mL Superdex 
75 column (GE Healthcare).  SipC200-295 shows little to no UV absorbance due to 
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the absence of aromatic residues in the construct.  The typical crystal 
morphology seen with SipC200-295 consisted of various spherulites and needle-like 
clusters that grew in a wide variety of low- to mid-range molecular weight PEG 
conditions (Fig. 22B).  Further screening with PEG-containing conditions; the 
addition of various additives; and reductive methlyation of SipC200-295 did not 









Figure 22.  The purification and crystallization of SipC200-295.  (A) SipC200-295 
elutes at approximately 65mL on a 120mL Superdex 75 column (GE Healthcare).  
Lane 1 (far left) contains the molecular weight marker, lane 2 is the column load 
material, and the remaining lanes are the fractions corresponding to the elution 
peak.  (B) Examples of the crystal morphologies seen with SipC200-295.  
Crystallization conditions are as follows: (1) 0.8M sodium phosphate/1.2M 
potassium phosphate, 0.1M acetate, pH 4.5; (2) 0.2M ammonium sulfate, 0.1M 
bis-tris, pH 5.5, 25% PEG 3350; (3) 1M sodium citrate, 0.1M tris, pH 7.0, 0.2M 













The most promising crystal morphology was obtained with SipC195-278 (Fig. 
23A), which produced birefringent needle spherulites (Fig. 23B).  Reductive 
methylation of the lysine residues of SipC195-278 led to the formation of thicker, 
individual needles (Fig. 23C); however, optimization of crystal conditions did not 
lead to crystals suitable for X-ray diffraction experiments.  Seeding using the 
methylated SipC195-278 needles was performed to encourage the growth of larger, 















Figure 23.  The purification and crystallization of SipC195-278.  (A) SipC195-278 
was purified on a 120mL Superdex 75 column (GE Healthcare) and eluted as a 
trimer at 67.68mL.  Lane 1 (far left) contains the molecular weight marker, lane 2 
is the column load material, and the remaining lanes are the fractions 
corresponding to the elution peak. (B) SipC195-278 produced a birefringent needle 
spherulite in 0.2M ammonium citrate, pH 7.0, 20% PEG 3350.  (C) Reductively 
methylated SipC195-278 produced thicker, individual needles.  The growth condition 








AI.3.2.3  Binding Partners 
 
 
As crystallization of the SipC C-terminal domain by itself did not lead to 
diffraction quality crystals, further work was aimed at purifying and crystallizing 
SipC in complex with potential C-terminal domain binding partners: ribosylated 
actin and mouse Exo70.  Crystallization with a binding partner often leads to 
stabilization of the protein of interest and can aid in successful crystallization.  
The C-terminal domain of SipC is known to polymerize monomeric actin to form 
actin filaments [30], so we examined the ability of SipC200-330, our largest stable 
SipC C-terminal domain construct, to form a complex with ribosylated actin.   
Ribosylated actin was produced by using SpvB, an ADP-ribosyltransferase 
effector protein from S. typhimurium [142], to modify monomeric actin with ADP-
ribose, thereby preventing actin polymerization and trapping it in its monomeric 
state.  ADP-ribosylation does not cause notable conformational change in actin 
[142]; therefore, we hypothesized that ribosylated actin could serve as a stable 
interacting partner with SipC200-320.    
 
In order to form a complex, SipC200-330 and ribosylated actin were 
incubated together as described and run over a 120mL Superdex 75 column (GE 
Healthcare).  A stable complex was not formed, as ribosylated actin and SipC200-
330 do not co-elute on the size exclusion column (Fig. 24).  It is possible that 
complex formation is not favored under the given conditions, or that ribosylated 
actin and/or the truncated C-terminal domain are not ideal interacting partners.  
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We also do not know how stable an interaction the SipC C-terminal domain has 
with monomeric actin.  The interaction may only be transient, and as a result, 























Figure 24.  SipC200-330 and ribosylated actin do not form a stable complex.  
SipC200-330 was incubated in a 1:1 molar ratio with ribosylated actin for 15 hours 
at 4°C, and then run over a 120mL Superdex 75 column (GE Healthcare).  
Ribosylated actin is approximately 45kD and elutes as a monomer, separately 
from 17kD SipC200-330.  SipC200-330 is not detected as a separate peak on the UV 
spectrum because it does not contain the aromatic residues necessary to give a 
substantial UV absorbance; however, a visible shift between SipC200-330 and 
ribosylated actin elution can be detected by SDS-PAGE.  .  Lane 1 (far left) 
contains the molecular weight marker, lane 2 is the column load material, Lane 3 
is another molecular weight marker, and the remaining lanes are the fractions 







Nichols, et al. reported that SipC200-409 interacts with the N-terminal 
domain of human Exo70 [138].  There are six isoforms of human Exo70, making 
in-house cloning of the gene problematic.  Additionally, the full-length clone was 
not available commercially, so we elected to work with mouse Exo70, a 653 
residue homolog that shares a 96% overall identity with human Exo70 but has an 
82 residue deletion in the N-terminal domain.  M. musculus Exo70 (mExo70) was 
soluble and stable when expressed with a large N-terminal tag, so experiments 
were performed with either a 63kD 6xHistidine-NusA tag or a 43kD maltose-
binding protein (MBP) tag on mExo70.   
 
Various methods for complex formation were investigated.  Purified SipC 
constructs, 195-400, 200-330, and 200-295, were mixed with purified mExo70 
constructs, 1-653 and 85-653, in a 1:1 molar ratio and incubated for 16 hours at 
4°C.  Stable complex formation was probed by size exclusion chromatography 
using a Superdex 200, 120mL column (GE Healthcare).  SipC and mExo70 did 
not form a complex, and eluted in individual peaks for all construct combinations 
analyzed.  Co-expression of histidine-tagged SipC200-409 and MBP-tagged 
mExo70 was also unsuccessful in forming a stable complex.  By co-expressing 
SipC200-409 with N-terminally 6x-histidine-NusA tagged mExo7085-653, we were 
able to pull-down SipC200-409 from cell lysate using NiNTA resin (Qiagen) (Fig. 
25).  The complex was not stable in the long-term, as SipC and mExo70 eluted 
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separately when run over a Superdex 200, 120mL column (GE Healthcare).  






















Figure 25.  Pull-down of SipC200-409 by histidine-NusA-tagged mExo7085-653.  
Histidine-NusA tagged mExo7085-653 and SipC200-409 were co-expressed and 
protein was loaded onto a NiNTA column (Qiagen).  The insoluble fraction is 
indicated with IS.  The column elution contains His-NusA-mExo7085-653 running at 



















AI.3.2.4  Actin Polymerization Assay 
 
 
In order to test our C-terminal domain SipC constructs for their ability to 
stimulate actin polymerization, we developed an assay based largely on an actin 
polymerization assay kit from Cytoskeleton, Inc. (Denver, CO) as well as the 
protocol detailed by Machesky, et al. [144].  The assay is performed with pyrene-
labeled actin (Cytoskeleton, Inc.), which emits a greater fluorescent signal when 
it is polymerized into F-actin [145].  Pyrene labeling does not alter the critical 
concentration of actin or interfere with normal filament formation [133].  We used 
Arp2/3 (Cytoskeleton, Inc.) in combination with the VCA domain of human 
Wiskott-Aldrich syndrome protein (WASp) (Cytoskeleton, Inc.) for a positive 
control of actin polymerization (Fig. 26).  The Arp 2/3 complex promotes actin 
filament nucleation in eukaryotic cells by binding to existing actin filaments and 
creating branch points for further filament formation [146].  Arp2/3 is able to 
stimulate rapid actin polymerization when bound to the C-terminal VCA domain 
conserved among WASp family members [147, 148].  When Arp2/3+VCA was 
added to pyrene-actin, a dramatic increase in pyrene fluorescence was observed 
(indicative of actin polymerization), leveling off approximately 10 minutes into the 












Figure 26.  SipC200-409 actin polymerization assay.  SipC200-409 did not show 
actin polymerization activity above the background; however, the positive control, 
Arp2/3 + VCA, successfully polymerizes pyrene-actin under the given conditions.  
Data shown is the average of two assay runs for each component. Standard error 
of the mean indicated with a black bar for each time point.  Reaction conditions 























































Our SipC200-409 construct did not show actin polymerization activity above 
that detected for actin alone (Fig. 26).  We initially performed this assay under the 
conditions described by Hayward, et al. [30], but when this proved unsuccessful, 
we sought to identify more ideal reaction conditions.  Hayward, et al. [30] and 
McGhie, et al. [134] used a 1:10 SipC to actin ratio for their polymerization 
assays, and the same buffer and assay conditions as are detailed in section 
AI.2.6.  We investigated a range of SipC to actin ratios, screening our SipC200-409 
and SipC195-400 constructs for activity with SipC to actin ratios ranging from 1:100 
to 5:1.  We also examined different buffer and salt conditions, and tried various 
pyrene-actin concentrations, including combinations of pyrene-actin and 
unlabeled actin.  No activity was detected under any of these reaction conditions.  
Urea denatured and refolded SipC200-409 was also tested for activity, and also 
gave a negative result.  Therefore, we were not able to show actin nucleation 


















AI.4  Conclusions 
 
 
SipC plays an integral part in Salmonella host entry, through its role as a 
translocase and through manipulation of the host cytoskeleton via actin 
nucleation and filament bundling.  We sought to define the structure of SipC in 
order to gain an understanding of how this protein is able to perform its many 
functions.  We investigated the N- and C-terminal effector domains of SipC as 
crystallization targets separately, and found that the N-terminal domain, SipC1-120, 
could not be purified in its native state, requiring denaturation and refolding in 
order to remain soluble in vitro. 
 
The C-terminal domain proved more amenable to in vitro work, and 
extensive crystallization screening was performed with different constructs of this 
SipC domain.  SipC200-295 and SipC195-278 led to spherulite and needle-like crystal 
formation in crystallization trials; however, efforts to optimize these initial hits did 
not lead to diffraction quality crystals.  A fluorescence-based assay was 
implemented to test for actin nucleation ability of SipC, although C-terminal 
domain constructs did not show activity in this assay.  These results are in 
contrast to the work published by Hayward, et al., which demonstrated actin 
nucleation activity of the SipC C-terminal domain using a similar fluorescence-
based approach with refolded SipC200-409 [30].  Our assays were performed with 
native SipC200-409 as well as denatured/refolded SipC200-409 under identical 
conditions as used by Hayward, et al. [30].  We were not able to replicate their 
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experiment under their described conditions, nor were we able to find more 
optimal conditions in which to detect actin nucleation activity.  One explanation 
for this discrepancy is that we used our own protocol for refolding SipC200-409; 
however, our refolded material was successfully refolded, as indicated by its 
elution profile by size exclusion chromatography, so we believe our protocol was 
adequate for proper protein folding.  It is still feasible that there were differences 
in refolding that might have led to our construct’s inactivity, so further 
experimentation will be necessary in order to rule out this possibility. 
 
Further examination of purification conditions for SipC domains could 
prove useful for successful crystallization.  Despite testing a variety of different 
conditions, our SipC constructs always behaved as multimers.  There may be a 
yet untested set of conditions that could yield monomeric material, potentially 
aiding in activity assaying as well as crystallization.  Cytokeratin 8 may serve as 
a better binding partner for SipC200-409 and this interaction has yet to be confirmed 














APPENDIX II.  AVIRULENCE PROTEIN A 
 
 
AII.1  Introduction 
 
 
Salmonella Avirulence Protein A (AvrA) is a SPI-1 encoded effector 
protein that is conditionally expressed in enteritis-related Salmonella strains, 
such as S. typhimurium [149, 150].  AvrA is a 34kD protein with a high sequence 
similarity, and 56% sequence identity, to Yersinia pseudotuberculosis YopJ [151].  
AvrA does not appear to be a phenocopy of YopJ, as AvrA and YopJ do not 
perform the same functions in host cells and are not interchangeable [152].  AvrA 
is predicted to contain a cysteine protease catalytic domain, comprised of 
His123-Glu142-Cys186, which is characteristic of Clan CE cysteine proteases 
(Fig. 27) [153].  Members of Clan CE are similar to those of Clan CA in that they 
both employ the same catalytic mechanism driven by an active cysteine thiol, but 
they differ in the arrangement of their triad residues.  AvrA is grouped into the 
YopJ-like C55 family within Clan CE, which contains members with sumoyl 





Figure 27.  A schematic representation of AvrA and its catalytic domain.  
AvrA is 302 residues in length and is hypothesized to contain a catalytic triad of 
His123, Glu142, and Cys186.  Gln180 aids in the formation of the oxyanion hole 



















AvrA’s involvement in cell infection remains poorly understood, as both 
AvrA’s catalytic function and targeted host signaling pathways are unclear.  AvrA 
does appear to have anti-apoptotic and anti-inflammatory effects on the host, and 
potential roles for AvrA include: stabilization of host cell permeability and tight 
junctions [149]; inhibition of the NF-κB signaling pathway [155]; counterbalance 
of the SPI-I TTSS effector activated JNK pathway and suppression of cell death 
[46, 156].  In order to carry out these functions in the host, AvrA has been 
attributed with having deubiquitinase and acetyltransferase activity.   
 
Deubiquitinases are cysteine proteases that cleave ubiquitin-protein 
bonds, preventing degradation of the targeted proteins.  Potential substrates of 
AvrA catalyzed deubiquitination are NF-κB, IκBα, β-catenin, and Wnt2 [46, 157, 
158].  Acetyltransferases, also commonly cysteine proteases, are responsible for 
the transfer of actyl groups to specific residues on their target protein.  AvrA O-
acetylates a key threonine residue located in the activation loop of MAPK kinase 
4, inhibiting JNK and subsequently leading to the attenuation of the host 
inflammatory response [159].  Through acetylation of p53, AvrA activates the p53 
pathway to stimulate cell cycle arrest and block apoptosis [160].  Inositol 
hexakisphosphate, a eukaryotic host cell factor, has been shown to stimulate 
AvrA’s acetyltransferase activity in vitro and is believed to serve as an allosteric 
activator of AvrA [161].  We sought to determine the X-ray structure of AvrA in 
order to gain a more precise understanding of its role in Salmonella infection. 
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AII.2  Materials and Methods 
 
 
AII.2.1  Protein Expression and Purification 
 
 
All AvrA constructs were amplified from Salmonella Typhimurium strain 
SL1344, and inserted into a modified pCDF-Duet-1 vector (Novagen) between 
the SalI and NotI restriction sites.  The catalytically inactive mutant, AvrAC186A, 
was generated by point mutagenesis.  Protein was expressed in E. coli 
BL21(DE3) cells with 1mM IPTG for 16 hours at 21°C.  Harvested cells were 
pelleted, resuspended in 50mM HEPES, pH 7.5, 300mM NaCl, and 5mM 
imidazole, and lysed via high-pressure homogenization.  Cleared lysate was run 
over Ni-NTA resin (Qiagen) and protein was eluted in 50mM HEPES, pH 7.5, 
300mM NaCl, and 500mM Imidazole.  Protein was dialyzed against 25mM 
HEPES, pH 7.5, 250mM NaCl, and 5mM DTT, and the N-terminal histidine tag 
was cleaved off with 6xHis-rhinovirus 3C protease.  The material was passed 
over Ni-NTA to remove the histidine tag and 3C protease.  The final purification 
step was size exclusion chromatography using a Superdex 75 column with a 
120mL resin volume (GE Healthcare).  All AvrA constructs were purified into 
25mM HEPES, pH 7.5, 250mM NaCl, and 5mM DTT.  
 
ARFGEF2 constructs were cloned out of human cDNA extracted from 
breast cancer cells (generously provided by L. Fish).  PCR products were 
inserted between SalI and NotI restriction sites in a modified pGEX4 vector (GE 
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Healthcare) that was engineered to contain a 6xHistidine tag followed by a 
rhinovirus 3C protease cleavage site all 3’ to the GST tag.  For co-expression of 
AvrA and ARFGEF2, ARFGEF2 was cloned between the SalI and NotI restriction 
sites of a modified pCDF-Duet-1 vector (Novagen) and AvrA was inserted 
between the NdeI and XhoI restriction sites.  Co-expression was also performed 
with AvrA in the first cloning site between SalI and NotI and ARFGEF2 in the 
second site between NdeI and XhoI.  Purification of ARFGEF2 alone and in 
combination with AvrA was performed as described for AvrA by itself. 
 
 
AII.2.2  Limited Proteolysis 
 
 
Limited proteolysis on 31.5μg of AvrA63-302 was performed using subtilisin 
protease (Sigma Aldrich), ranging from 3.25ng to 1.89μg, with 5mM CaCl2.  The 
reaction was allowed to proceed at room temperature for 20 minutes, and was 
stopped with the addition of 10mM PMSF and SDS loading buffer.  Reaction 
products were separated via 15% SDS-PAGE and were transferred to PVDF 
membrane (Millipore) for visualization by SYPRO® Ruby protein stain (Sigma 
Aldrich).  Major cleavage product bands were excised from the membrane and 
sent to the Columbia University Protein Core Facility (New York, NY) for N-







AII.2.3  Yeast Two-Hybrid Sample Preparation 
 
 
AvrA15-302 and catalytically inactive AvrA15-302, C186A were cloned into the 
pGBT9 vector (Clontech Laboratories, Inc.) between the EcoRI and SalI 
restriction sites.  The vectors containing the AvrA bait constructs were sent to the 
Protein Interaction Screening department of the Genomics and Proteomics Core 
Facility at the German Cancer Research Center (Heidelberg, Germany) for yeast 
two-hybrid screening.  A pre-screen with varying 3-aminotriazole concentrations 
was performed using both wild-type and the catalytic mutant of AvrA15-302.  It was 
determined that AvrA15-302, C186A could be screened at a higher stringency with 
positive hits clearly above the background, so the catalytic mutant was used in 
four independent screens using a human universal normalized cDNA library with 

























AII.3.1  Domain Determination and Purification 
 
 
 In order to obtain a structure of AvrA, we tested various constructs for their 
crystallization propensity (Table 5).  Full-length AvrA was poorly soluble, but it 
was it was found that expression of AvrA15-302 led to a significantly higher protein 
yield.  Limited proteolysis of AvrA15-302 using subtilisin protease identified new 
constructs with further N-terminal truncations, AvrA27-302 and AvrA63-302.   Of the 
constructs screened, AvrA63-302 provided the greatest yield of 14.2mg of protein 
per liter of culture grown.  Treatment of AvrA63-302 with subtilisin protease 
revealed C-terminal truncations at residues 275, 258, and 244, estimated based 
on molecular weight of the cleavage products (Fig. 28).  Additional C-terminal 
truncations, at 220 and 214, resulted in insoluble constructs.  
 
















Residue! MW (kD)! pI! Soluble! Yield!
(mg/L)!
1-302! 33.7! 5.4! Y! 0.3!
15-302! 32! 5.4! Y! 4.7!
27-302! 31! 5.3! Y! 7.9!
63-302! 27! 6.2! Y! 14.2!
63-244! 20.5! 5.3! Y! 10.8!
63-220! 17.7! 4.8! N! N/A!















Figure 28.  Limited proteolysis of AvrA63-302.  AvrA63-302 was treated with 
subtilisin protease, ranging from 3.25ng to 1.89μg, for 20 minutes at room 
temperature.  There were three main cleavage products, all of which were the 
result of C-terminal cleavage.  The products correspond to construct of 63-275, 




AvrA63-244 was soluble with an N-terminal histidine tag, and yielded 
approximately 10.8mg of protein per liter of culture grown.  The final step in the 
purification of this construct is shown in Figure 29.  On the Superdex 75, 120mL 
column under the given conditions, AvrA63-244 runs as both a dimer and 
monomer, eluting at 61.16mL and 70.58mL, respectively.  Crystal screens were 
performed using the monomeric material, but did not lead to crystals.  None of 
the AvrA constructs successfully crystallized; therefore, we attempted to find a 











































Figure 29.  The purification of AvrA63-244.  AvrA63-244 was purified on a 
Superdex 75, 120mL column (GE Healthcare) into 25mM HEPES, pH 7.5, 
250mM NaCl, and 5mM DTT.  There are two elution peaks, corresponding to 
elution as a dimer (61.16mL) and as a monomer (70.58mL).  Lane 1 (far left) 
contains the molecular weight marker, lane 2 is the column load material, and the 
remaining lanes are the fractions corresponding to the elution peak.  
 
 
AII.3.2  ARFGEF2: A Potential Binding Partner 
 
 
To identify a potential binding partner for AvrA, we contracted with the 







(Heidelberg, Germany) to perform a yeast two-hybrid screen using catalytically 
inactive AvrA15-302, C186A as bait.  A yeast two-hybrid screen is a method for 
probing the interaction between two proteins.  The protein of interest is used as 
the bait, and is expressed in yeast cells containing a prey plasmid generated 
from a cDNA library that is derived from the organism or tissue of choice.   
 
 
Table 6.  Yeast two-hybrid results.  AvrA15-302, C186A was used as bait in four 
independent yeast two-hybrid screens against a human universal normalized 




Four independent screens were executed against a human universal 
normalized cDNA library at the lowest stringency level possible using 0mM 3-
aminotriazole.  Three prey proteins were identified as potential interacting 
partners with the catalytically inactivate AvrA15-302: Brefeldin A-inhibited Guanine 
Nucleotide Exchange Protein 2 (ARFGEF2); ASAP1 intronic transcript 1 (ASAP1-
IT1); ankyrin 3, node of Ranvier (ANK3).  The results are summarized in Table 6.  
ANK3 was isolated two times in the screening process; however the isolated 
fragments were all located in the 5’ untranslated region (UTR).  ASAP1-IT1 was 












starts in 3’ 
UTR!





Avg. No. of 
bases of 5’ 




ARFGEF2! 3! 0! 0! 3! 0! 1!
ASAP1-IT1!
(non-protein)!
2! 0! 0! 2! 0! 2!
ANK3! 2! 2! 0! 0! 618! 5!
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likely an artifact as it is a non-protein coding sequence.  ARFGEF2 was the most 
promising result of this experiment.  ARFGEF2 was isolated in three out of the 
four screens, and in all three instances, the isolated fragment started in the 
coding sequence of the protein.  ARFGEF2 also had a prey promiscuity of 1, 
which indicates that this bait/prey pair is highly specific.   
 
The isolated fragment of ARFGEF2 corresponds to the C-terminal domain 
of the protein, spanning residues 1638 to 1786.  ARFGEF2 is a large, 200kD 
guanine nucleotide exchange factor that is required for vesicle trafficking from the 
trans-Golgi network [162].  ARFGEF2 stimulates the exchange of GDP for GTP 
to activate ADP-ribosylation factors (ARFs), which then assemble coat proteins 
around intracellular vesicles, mediating vesicle cycling between the trans-Golgi 
network, endosome, and plasma membrane [163, 164].  The nucleotide 
exchange activity of ARFGEF2 is attributed to the presence of a Sec7 domain, 
correlating to residues 644 to 832 (Fig. 30A).  The Sec7 domain was originally 
identified in yeast and is highly conserved in proteins possessing GEF activity 
[165].  ARFGEF2 has also been found to associate with recycling endosome-like 
peripheral vesicles and has been implicated in the coordination of actin 
cytoskeleton mechanics and membrane traffic in cell migration via an interaction 
with integrin β1 [166].  The C-terminal domain of ARFGEF2 has not been 
associated with a specific function; however, it is possible that AvrA’s interaction 
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with this domain could affect ARFGEF2’s role in vesicular transport and/or in 



















Figure 30.  The AvrA interacting domain of ARFGEF2 and its purification.  
Through a yeast two-hybrid screen, the C-terminal domain of ARFGEF2, 
residues 1638 to 1786 (orange), was identified as a potential binding partner of 
AvrA15-302, C186A.  (A) ARFGEF2 is 1786 residues in length and contains a Sec7 
domain.  The initial ARFGEF2 constructs designed to probe for AvrA interaction 
had N-terminal starts at residues 1490, 1510, and 1520, respectively, and all 
ended at residue 1786.  (B) ARFGEF2 constructs were expressed with N-
terminal GST-6xHis tags, running at approximately 55-60kD.  All constructs were 
found in the insoluble fraction, which is denoted as IS, the soluble fraction as S, 
and the Ni-NTA elution as Eln.  The first lane on each gel (far left) contains the 























In order to confirm the interaction between AvrA and the C-terminal 
domain of ARFGEF2, we designed three ARFGEF2 constructs based on 
secondary structure predictions generated by Phyre [167].  Constructs started at 
residue 1490, 1510, and 1520, and all terminated with residue 1786 (Fig. 30A).  
These constructs were expressed with an N-terminal GST-6xHis tag and purified 
over a Ni-NTA column (Fig. 30B).  All constructs were insoluble. 
 
We also investigated the complex formation between AvrA and ARFGEF2 
by co-expressing AvrA15-302, C186A and ARFGEF2 on separate plasmids, pCDF-
Duet-1 (Novagen) for AvrA and pGEX4 (GE Healthcare) for ARFGEF2, in the 
same E. coli cells.  Expression was seen for AvrA15-302, C186A, but not for 
ARFGEF2.  Co-expression from the same vector, pCDF-Duet-1 (Novagen), was 
also examined, looking at His-tagged ARFGEF2 with untagged AvrA15-302, C186A as 
well as His-tagged AvrA15-203, C186A with untagged ARFGEF2.  His-tagged AvrA15-
302, C186A was soluble and could be purified on Ni-NTA resin, while untagged 














AII.4  Conclusions 
 
 
We have defined a minimal domain of AvrA, which spans residues 63 to 
244, and contains the predicted catalytic triad of AvrA.  Although under the given 
purification conditions, AvrA63-244 was not successful in crystallization trials, more 
work can be done to refine the purification conditions and identify those in which 
the protein behaves in a uniform state in solution, either as a dimer or a 
monomer.  Through a yeast two-hybrid screen, we found the C-terminal domain 
of ARFGEF2, residues 1638 to 1786, to be a potential interacting partner of AvrA.  
Although co-expression of ARFGEF2 C-terminal domain constructs with AvrA did 
not yield an AvrA-ARFGEF2 complex, it may prove successful to purify the GST-
His-ARFGEF2 constructs under denaturing conditions, refold, and then probe for 
binding to AvrA15-302, C186A.  The interaction could also be examined through co-
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